IE19922897A1 - Solubility parameter based drug delivery system and method for altering drug saturation concentration - Google Patents
Solubility parameter based drug delivery system and method for altering drug saturation concentrationInfo
- Publication number
- IE19922897A1 IE19922897A1 IE1992/2897A IE922897A IE19922897A1 IE 19922897 A1 IE19922897 A1 IE 19922897A1 IE 1992/2897 A IE1992/2897 A IE 1992/2897A IE 922897 A IE922897 A IE 922897A IE 19922897 A1 IE19922897 A1 IE 19922897A1
- Authority
- IE
- Ireland
- Prior art keywords
- delivery system
- drug delivery
- transdermal drug
- drug
- sensitive adhesive
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims description 260
- 229940079593 drugs Drugs 0.000 title claims description 249
- 239000000203 mixture Substances 0.000 claims description 163
- 229920000642 polymer Polymers 0.000 claims description 121
- 230000001070 adhesive Effects 0.000 claims description 109
- 239000000853 adhesive Substances 0.000 claims description 104
- -1 tratoquinol Chemical compound 0.000 claims description 90
- 229920001296 polysiloxane Polymers 0.000 claims description 86
- 229920000058 polyacrylate Polymers 0.000 claims description 71
- 230000004907 flux Effects 0.000 claims description 56
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims description 48
- SNIOPGDIGTZGOP-UHFFFAOYSA-N 1,2,3-propanetrioltrinitrate Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 claims description 47
- 229940014995 Nitroglycerin Drugs 0.000 claims description 41
- 239000000006 Nitroglycerin Substances 0.000 claims description 41
- 229960003711 glyceryl trinitrate Drugs 0.000 claims description 41
- 239000000463 material Substances 0.000 claims description 41
- 239000003795 chemical substances by application Substances 0.000 claims description 40
- 239000011159 matrix material Substances 0.000 claims description 40
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 31
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 claims description 27
- 229960001652 norethindrone acetate Drugs 0.000 claims description 26
- 230000002500 effect on skin Effects 0.000 claims description 24
- 229960005309 Estradiol Drugs 0.000 claims description 21
- 229940023808 Albuterol Drugs 0.000 claims description 19
- NDAUXUAQIAJITI-UHFFFAOYSA-N Salbutamol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims description 19
- 229960002052 salbutamol Drugs 0.000 claims description 19
- 230000000975 bioactive Effects 0.000 claims description 18
- 230000002708 enhancing Effects 0.000 claims description 18
- 239000000262 estrogen Substances 0.000 claims description 17
- 229960001416 pilocarpine Drugs 0.000 claims description 17
- QCHFTSOMWOSFHM-WPRPVWTQSA-N Pilopine HS Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 claims description 16
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 16
- 230000000051 modifying Effects 0.000 claims description 15
- 238000009792 diffusion process Methods 0.000 claims description 14
- 239000003623 enhancer Substances 0.000 claims description 14
- 239000000583 progesterone congener Substances 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 12
- 230000001965 increased Effects 0.000 claims description 10
- 239000006184 cosolvent Substances 0.000 claims description 9
- 230000000561 anti-psychotic Effects 0.000 claims description 8
- 239000000945 filler Substances 0.000 claims description 8
- 150000003431 steroids Chemical class 0.000 claims description 8
- LNEPOXFFQSENCJ-UHFFFAOYSA-N Haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims description 7
- 239000000048 adrenergic agonist Substances 0.000 claims description 7
- 239000000064 cholinergic agonist Substances 0.000 claims description 7
- 229960003878 haloperidol Drugs 0.000 claims description 7
- 239000004041 inotropic agent Substances 0.000 claims description 7
- 230000002936 tranquilizing Effects 0.000 claims description 7
- 239000003204 tranquilizing agent Substances 0.000 claims description 7
- VREFGVBLTWBCJP-UHFFFAOYSA-N Alprazolam Chemical group C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 claims description 6
- HJJPJSXJAXAIPN-UHFFFAOYSA-N Arecoline Chemical compound COC(=O)C1=CCCN(C)C1 HJJPJSXJAXAIPN-UHFFFAOYSA-N 0.000 claims description 6
- OROGSEYTTFOCAN-DNJOTXNNSA-N Codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims description 6
- 210000004207 Dermis Anatomy 0.000 claims description 6
- 229940011871 Estrogens Drugs 0.000 claims description 6
- 229940053934 Norethindrone Drugs 0.000 claims description 6
- VIKNJXKGJWUCNN-XGXHKTLJSA-N Norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 claims description 6
- 229940030484 SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM ESTROGENS Drugs 0.000 claims description 6
- 229960004538 alprazolam Drugs 0.000 claims description 6
- 229940046080 endocrine therapy drugs Estrogens Drugs 0.000 claims description 6
- 229960000993 norethisterone Drugs 0.000 claims description 6
- DOMWKUIIPQCAJU-LJHIYBGHSA-N 17-Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 claims description 5
- NVUUMOOKVFONOM-GPBSYSOESA-N 19-Norprogesterone Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 NVUUMOOKVFONOM-GPBSYSOESA-N 0.000 claims description 5
- VUHJZBBCZGVNDZ-TTYLFXKOSA-N Chlormadinone Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 VUHJZBBCZGVNDZ-TTYLFXKOSA-N 0.000 claims description 5
- 229960001076 Chlorpromazine Drugs 0.000 claims description 5
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N Chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 claims description 5
- JWAHBTQSSMYISL-MHTWAQMVSA-N Demegestone Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(C)[C@@]1(C)CC2 JWAHBTQSSMYISL-MHTWAQMVSA-N 0.000 claims description 5
- RGLYKWWBQGJZGM-ISLYRVAYSA-N Diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 claims description 5
- LVHOURKCKUYIGK-RGUJTQARSA-N Dimethisterone Chemical compound C1([C@@H](C)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C#CC)(O)[C@@]2(C)CC1 LVHOURKCKUYIGK-RGUJTQARSA-N 0.000 claims description 5
- JGMOKGBVKVMRFX-HQZYFCCVSA-N Dydrogesterone Chemical compound C1=CC2=CC(=O)CC[C@@]2(C)[C@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 JGMOKGBVKVMRFX-HQZYFCCVSA-N 0.000 claims description 5
- WKRLQDKEXYKHJB-HFTRVMKXSA-N Equilin Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 WKRLQDKEXYKHJB-HFTRVMKXSA-N 0.000 claims description 5
- PROQIPRRNZUXQM-ZXXIGWHRSA-N Estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 claims description 5
- 229960001348 Estriol Drugs 0.000 claims description 5
- 229960003399 Estrone Drugs 0.000 claims description 5
- HZEQBCVBILBTEP-ZFINNJDLSA-N Estropipate Chemical compound C1CNCCN1.OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 HZEQBCVBILBTEP-ZFINNJDLSA-N 0.000 claims description 5
- 229960000445 Ethisterone Drugs 0.000 claims description 5
- CHNXZKVNWQUJIB-CEGNMAFCSA-N Ethisterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 CHNXZKVNWQUJIB-CEGNMAFCSA-N 0.000 claims description 5
- 229940012028 Ethynodiol Diacetate Drugs 0.000 claims description 5
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Hiestrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 claims description 5
- YNVGQYHLRCDXFQ-XGXHKTLJSA-N Lynestrenol Chemical compound C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 YNVGQYHLRCDXFQ-XGXHKTLJSA-N 0.000 claims description 5
- 229960004296 Megestrol Acetate Drugs 0.000 claims description 5
- 229960004805 Melengestrol Drugs 0.000 claims description 5
- OKHAOBQKCCIRLO-IBVJIVQJSA-N Melengestrol Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(=C)[C@@](C(=O)C)(O)[C@@]1(C)CC2 OKHAOBQKCCIRLO-IBVJIVQJSA-N 0.000 claims description 5
- IMSSROKUHAOUJS-MJCUULBUSA-N Mestranol Chemical compound C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 IMSSROKUHAOUJS-MJCUULBUSA-N 0.000 claims description 5
- 229960001390 Mestranol Drugs 0.000 claims description 5
- 229960001858 Norethynodrel Drugs 0.000 claims description 5
- ICTXHFFSOAJUMG-SLHNCBLASA-N Norethynodrel Chemical compound C1CC(=O)CC2=C1[C@H]1CC[C@](C)([C@](CC3)(O)C#C)[C@@H]3[C@@H]1CC2 ICTXHFFSOAJUMG-SLHNCBLASA-N 0.000 claims description 5
- 229940053938 Norgestrel Drugs 0.000 claims description 5
- 229960000762 Perphenazine Drugs 0.000 claims description 5
- WWYNJERNGUHSAO-XUDSTZEESA-N Previfem Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 claims description 5
- RJKFOVLPORLFTN-STHVQZNPSA-N Progesterone Natural products O=C(C)[C@@H]1[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1 RJKFOVLPORLFTN-STHVQZNPSA-N 0.000 claims description 5
- QFFCYTLOTYIJMR-XMGTWHOFSA-N Promegestone Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@@](C(=O)CC)(C)[C@@]1(C)CC2 QFFCYTLOTYIJMR-XMGTWHOFSA-N 0.000 claims description 5
- RJKFOVLPORLFTN-LEKSSAKUSA-N Syngestrets Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 5
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Tranquisan Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 claims description 5
- NNJVILVZKWQKPM-UHFFFAOYSA-N Xylocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 5
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N [(8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 claims description 5
- 239000000654 additive Substances 0.000 claims description 5
- 229960003996 chlormadinone Drugs 0.000 claims description 5
- 229940035811 conjugated estrogens Drugs 0.000 claims description 5
- 229960001853 demegestone Drugs 0.000 claims description 5
- 229960000452 diethylstilbestrol Drugs 0.000 claims description 5
- 229950006690 dimethisterone Drugs 0.000 claims description 5
- 229960004913 dydrogesterone Drugs 0.000 claims description 5
- 229950008385 estrone sulphate Drugs 0.000 claims description 5
- 229940081345 estropipate Drugs 0.000 claims description 5
- 229960000218 etynodiol Drugs 0.000 claims description 5
- 229950000801 hydroxyprogesterone caproate Drugs 0.000 claims description 5
- 229960004400 levonorgestrel Drugs 0.000 claims description 5
- 229960004194 lidocaine Drugs 0.000 claims description 5
- 229960003387 progesterone Drugs 0.000 claims description 5
- 239000000186 progesterone Substances 0.000 claims description 5
- 229960001584 promegestone Drugs 0.000 claims description 5
- DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 claims description 4
- AAOVKJBEBIDNHE-UHFFFAOYSA-N Diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims description 4
- 229960002690 Fluphenazine Drugs 0.000 claims description 4
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine dihydrochloride Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 claims description 4
- 229960003904 Triflupromazine Drugs 0.000 claims description 4
- XSCGXQMFQXDFCW-UHFFFAOYSA-N Triflupromazine Chemical compound C1=C(C(F)(F)F)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 XSCGXQMFQXDFCW-UHFFFAOYSA-N 0.000 claims description 4
- 230000003247 decreasing Effects 0.000 claims description 4
- 229960003529 diazepam Drugs 0.000 claims description 4
- 229960002985 medroxyprogesterone acetate Drugs 0.000 claims description 4
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 claims description 4
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 claims description 3
- GJSURZIOUXUGAL-UHFFFAOYSA-N 2-((2,6-Dichlorophenyl)imino)imidazolidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 claims description 3
- RSDQHEMTUCMUPQ-UHFFFAOYSA-N 5-[1-hydroxy-2-(propan-2-ylamino)ethyl]quinolin-8-ol Chemical compound C1=CC=C2C(C(O)CNC(C)C)=CC=C(O)C2=N1 RSDQHEMTUCMUPQ-UHFFFAOYSA-N 0.000 claims description 3
- WNTYBHLDCKXEOT-UHFFFAOYSA-N Acetophenazine Chemical compound C12=CC(C(=O)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(CCO)CC1 WNTYBHLDCKXEOT-UHFFFAOYSA-N 0.000 claims description 3
- 229960004373 Acetylcholine Drugs 0.000 claims description 3
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 claims description 3
- 229960005274 Benzocaine Drugs 0.000 claims description 3
- BLFLLBZGZJTVJG-UHFFFAOYSA-N Benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 claims description 3
- NZUPCNDJBJXXRF-UHFFFAOYSA-O Bethanechol Chemical compound C[N+](C)(C)CC(C)OC(N)=O NZUPCNDJBJXXRF-UHFFFAOYSA-O 0.000 claims description 3
- XWTYSIMOBUGWOL-UHFFFAOYSA-N Bricaril Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims description 3
- RKLNONIVDFXQRX-UHFFFAOYSA-N Bromperidol Chemical compound C1CC(O)(C=2C=CC(Br)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 RKLNONIVDFXQRX-UHFFFAOYSA-N 0.000 claims description 3
- LEBVLXFERQHONN-UHFFFAOYSA-N Bupivacaine Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 claims description 3
- 229960004484 CARBACHOL Drugs 0.000 claims description 3
- FAKRSMQSSFJEIM-RQJHMYQMSA-N Captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims description 3
- AIXAANGOTKPUOY-UHFFFAOYSA-N Carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 claims description 3
- KEMXXQOFIRIICG-UHFFFAOYSA-N Carbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(NC(N)=O)=C1 KEMXXQOFIRIICG-UHFFFAOYSA-N 0.000 claims description 3
- 229960004782 Chlordiazepoxide Drugs 0.000 claims description 3
- ANTSCNMPPGJYLG-UHFFFAOYSA-N Chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 claims description 3
- 229960002155 Chlorothiazide Drugs 0.000 claims description 3
- 229960001231 Choline Drugs 0.000 claims description 3
- DGBIGWXXNGSACT-UHFFFAOYSA-N Clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 claims description 3
- HSUGRBWQSSZJOP-RTWAWAEBSA-N Diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 claims description 3
- 229960000385 Dyclonine Drugs 0.000 claims description 3
- BZEWSEKUUPWQDQ-UHFFFAOYSA-N Dyclonine Chemical compound C1=CC(OCCCC)=CC=C1C(=O)CCN1CCCCC1 BZEWSEKUUPWQDQ-UHFFFAOYSA-N 0.000 claims description 3
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 claims description 3
- 229960003976 Etidocaine Drugs 0.000 claims description 3
- LSLYOANBFKQKPT-UHFFFAOYSA-N Fenoterol Chemical compound C=1C(O)=CC(O)=CC=1C(O)CNC(C)CC1=CC=C(O)C=C1 LSLYOANBFKQKPT-UHFFFAOYSA-N 0.000 claims description 3
- PJMPHNIQZUBGLI-UHFFFAOYSA-N Fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims description 3
- 229960002428 Fentanyl Drugs 0.000 claims description 3
- SAADBVWGJQAEFS-UHFFFAOYSA-N Flurazepam Chemical compound N=1CC(=O)N(CCN(CC)CC)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F SAADBVWGJQAEFS-UHFFFAOYSA-N 0.000 claims description 3
- 229960003528 Flurazepam Drugs 0.000 claims description 3
- 229960002479 Isosorbide Drugs 0.000 claims description 3
- 229960000201 Isosorbide Dinitrate Drugs 0.000 claims description 3
- MOYKHGMNXAOIAT-JGWLITMVSA-N Isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 claims description 3
- DIWRORZWFLOCLC-UHFFFAOYSA-N Lorazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-UHFFFAOYSA-N 0.000 claims description 3
- XJGVXQDUIWGIRW-UHFFFAOYSA-N Loxapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 XJGVXQDUIWGIRW-UHFFFAOYSA-N 0.000 claims description 3
- 229960000300 Mesoridazine Drugs 0.000 claims description 3
- SLVMESMUVMCQIY-UHFFFAOYSA-N Mesoridazine Chemical compound CN1CCCCC1CCN1C2=CC(S(C)=O)=CC=C2SC2=CC=CC=C21 SLVMESMUVMCQIY-UHFFFAOYSA-N 0.000 claims description 3
- 229960002329 Methacholine Drugs 0.000 claims description 3
- KLPWJLBORRMFGK-UHFFFAOYSA-N Molindone Chemical compound O=C1C=2C(CC)=C(C)NC=2CCC1CN1CCOCC1 KLPWJLBORRMFGK-UHFFFAOYSA-N 0.000 claims description 3
- UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 claims description 3
- HHRNQOGXBRYCHF-UHFFFAOYSA-N N-[2-hydroxy-5-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl]methanesulfonamide Chemical compound CC(C)NCC(O)C1=CC=C(O)C(NS(C)(=O)=O)=C1 HHRNQOGXBRYCHF-UHFFFAOYSA-N 0.000 claims description 3
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 claims description 3
- 229960001783 Nicardipine Drugs 0.000 claims description 3
- 229960002715 Nicotine Drugs 0.000 claims description 3
- SNICXCGAKADSCV-JTQLQIEISA-N Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 3
- HYIMSNHJOBLJNT-UHFFFAOYSA-N Nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims description 3
- 229960001597 Nifedipine Drugs 0.000 claims description 3
- LMOINURANNBYCM-UHFFFAOYSA-N Orciprenaline Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 claims description 3
- ADIMAYPTOBDMTL-UHFFFAOYSA-N Oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 claims description 3
- 229960004265 Piperacetazine Drugs 0.000 claims description 3
- BTFMCMVEUCGQDX-UHFFFAOYSA-N Piperacetazine Chemical compound C12=CC(C(=O)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCC(CCO)CC1 BTFMCMVEUCGQDX-UHFFFAOYSA-N 0.000 claims description 3
- IENZQIKPVFGBNW-UHFFFAOYSA-N Prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 claims description 3
- 229960001289 Prazosin Drugs 0.000 claims description 3
- MVFGUOIZUNYYSO-UHFFFAOYSA-N Prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 claims description 3
- REQCZEXYDRLIBE-UHFFFAOYSA-N Procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 claims description 3
- MFDFERRIHVXMIY-UHFFFAOYSA-N Procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims description 3
- AQHHHDLHHXJYJD-UHFFFAOYSA-N Proprasylyt Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims description 3
- LOUPRKONTZGTKE-LHHVKLHASA-N Quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 claims description 3
- 229960004482 Quinidine Sulfate Drugs 0.000 claims description 3
- IYMMESGOJVNCKV-SKDRFNHKSA-N Rimiterol Chemical compound C([C@@H]1[C@@H](O)C=2C=C(O)C(O)=CC=2)CCCN1 IYMMESGOJVNCKV-SKDRFNHKSA-N 0.000 claims description 3
- 229950010289 SOTERENOL Drugs 0.000 claims description 3
- 229960000195 Terbutaline Drugs 0.000 claims description 3
- 229960002372 Tetracaine Drugs 0.000 claims description 3
- GKCBAIGFKIBETG-UHFFFAOYSA-N Tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 claims description 3
- AIUHRQHVWSUTGJ-UHFFFAOYSA-N Thiopropazate Chemical compound C1CN(CCOC(=O)C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 AIUHRQHVWSUTGJ-UHFFFAOYSA-N 0.000 claims description 3
- GFBKORZTTCHDGY-UWVJOHFNSA-N Thiothixene Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2\C1=C\CCN1CCN(C)CC1 GFBKORZTTCHDGY-UWVJOHFNSA-N 0.000 claims description 3
- JOFWLTCLBGQGBO-UHFFFAOYSA-N Triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 claims description 3
- 229960002324 Trifluoperazine Drugs 0.000 claims description 3
- ZEWQUBUPAILYHI-UHFFFAOYSA-N Trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 claims description 3
- SGTNSNPWRIOYBX-UHFFFAOYSA-N Verapamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims description 3
- 229960000276 acetophenazine Drugs 0.000 claims description 3
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 claims description 3
- 230000000996 additive Effects 0.000 claims description 3
- 229960000910 bethanechol Drugs 0.000 claims description 3
- 229960004037 bromperidol Drugs 0.000 claims description 3
- 229960003150 bupivacaine Drugs 0.000 claims description 3
- RMRJXGBAOAMLHD-CTAPUXPBSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-CTAPUXPBSA-N 0.000 claims description 3
- 229960001736 buprenorphine Drugs 0.000 claims description 3
- 229960000830 captopril Drugs 0.000 claims description 3
- 229960001386 carbuterol Drugs 0.000 claims description 3
- 229960003120 clonazepam Drugs 0.000 claims description 3
- 229960002896 clonidine Drugs 0.000 claims description 3
- 229960003920 cocaine Drugs 0.000 claims description 3
- ZPUCINDJVBIVPJ-BARDWOONSA-N cocaine Natural products O([C@@H]1C[C@H]2CC[C@H](N2C)[C@@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-BARDWOONSA-N 0.000 claims description 3
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 3
- 229960004126 codeine Drugs 0.000 claims description 3
- 229960004166 diltiazem Drugs 0.000 claims description 3
- 229960001022 fenoterol Drugs 0.000 claims description 3
- 229960004391 lorazepam Drugs 0.000 claims description 3
- 229960000423 loxapine Drugs 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 claims description 3
- 229960002409 mepivacaine Drugs 0.000 claims description 3
- 229940054556 metaproterenol Drugs 0.000 claims description 3
- NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 claims description 3
- 229960004938 molindone Drugs 0.000 claims description 3
- 229930015196 nicotine Natural products 0.000 claims description 3
- 229960002657 orciprenaline Drugs 0.000 claims description 3
- 229960004535 oxazepam Drugs 0.000 claims description 3
- 229960001807 prilocaine Drugs 0.000 claims description 3
- 229960000244 procainamide Drugs 0.000 claims description 3
- 229960004919 procaine Drugs 0.000 claims description 3
- 229960003712 propranolol Drugs 0.000 claims description 3
- 229960001457 rimiterol Drugs 0.000 claims description 3
- 229960004728 thiopropazate Drugs 0.000 claims description 3
- 229960004660 thiothixene Drugs 0.000 claims description 3
- 229960004605 timolol Drugs 0.000 claims description 3
- 229960003386 triazolam Drugs 0.000 claims description 3
- 229960001722 verapamil Drugs 0.000 claims description 3
- 210000003169 Central Nervous System Anatomy 0.000 claims description 2
- PUFQVTATUTYEAL-UHFFFAOYSA-N Cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 claims description 2
- 229940120099 Dibucaine Drugs 0.000 claims description 2
- WYCLKVQLVUQKNZ-UHFFFAOYSA-N Halazepam Chemical compound N=1CC(=O)N(CC(F)(F)F)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 WYCLKVQLVUQKNZ-UHFFFAOYSA-N 0.000 claims description 2
- 229960004856 Prazepam Drugs 0.000 claims description 2
- MWQCHHACWWAQLJ-UHFFFAOYSA-N Prazepam Chemical compound O=C1CN=C(C=2C=CC=CC=2)C2=CC(Cl)=CC=C2N1CC1CC1 MWQCHHACWWAQLJ-UHFFFAOYSA-N 0.000 claims description 2
- 229960001747 cinchocaine Drugs 0.000 claims description 2
- KLBQZWRITKRQQV-UHFFFAOYSA-N dl-Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 claims description 2
- 229960002158 halazepam Drugs 0.000 claims description 2
- 229960002784 thioridazine Drugs 0.000 claims description 2
- 230000003444 anaesthetic Effects 0.000 claims 6
- 229960003515 Bendroflumethiazide Drugs 0.000 claims 4
- BFPYWIDHMRZLRN-SLHNCBLASA-N Etivex Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 claims 4
- ONKUMRGIYFNPJW-KIEAKMPYSA-N Etynodiol diacetate Chemical compound C1C[C@]2(C)[C@@](C#C)(OC(C)=O)CC[C@H]2[C@@H]2CCC3=C[C@@H](OC(=O)C)CC[C@@H]3[C@H]21 ONKUMRGIYFNPJW-KIEAKMPYSA-N 0.000 claims 4
- 230000000202 analgesic Effects 0.000 claims 4
- HDWIHXWEUNVBIY-UHFFFAOYSA-N bendroflumethiazidum Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1=CC=CC=C1 HDWIHXWEUNVBIY-UHFFFAOYSA-N 0.000 claims 4
- 229960002568 ethinylestradiol Drugs 0.000 claims 4
- 229950001879 Salmefamol Drugs 0.000 claims 2
- VPMWDFRZSIMDKW-YJYMSZOUSA-N Salmefamol Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 VPMWDFRZSIMDKW-YJYMSZOUSA-N 0.000 claims 2
- CRBHXDCYXIISFC-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CC[O-] CRBHXDCYXIISFC-UHFFFAOYSA-N 0.000 claims 2
- YIPYJRPRHUJJDP-WKOLOUIMSA-N [(8S,9S,10R,13S,14S,17S)-17-acetyl-10,13-dimethyl-2,7,8,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate Chemical compound C1C[C@@H]2[C@](CCC(OC(=O)C)=C3)(C)C3=CC[C@H]2[C@@H]2CC[C@H](C(C)=O)[C@]21C YIPYJRPRHUJJDP-WKOLOUIMSA-N 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 210000003491 Skin Anatomy 0.000 description 41
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 26
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N Oleic acid Natural products CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 24
- 238000000338 in vitro Methods 0.000 description 19
- 239000002904 solvent Substances 0.000 description 19
- 239000004615 ingredient Substances 0.000 description 15
- 238000009472 formulation Methods 0.000 description 13
- 235000013772 propylene glycol Nutrition 0.000 description 13
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 12
- 229940067606 Lecithin Drugs 0.000 description 12
- 239000000787 lecithin Substances 0.000 description 12
- 235000010445 lecithin Nutrition 0.000 description 12
- 235000021313 oleic acid Nutrition 0.000 description 12
- 239000005642 Oleic acid Substances 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 239000012530 fluid Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- SZXQTJUDPRGNJN-UHFFFAOYSA-N Dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 9
- 239000000969 carrier Substances 0.000 description 9
- 229920002959 polymer blend Polymers 0.000 description 9
- URZHQOCYXDNFGN-UHFFFAOYSA-N 2,4,6-trimethyl-2,4,6-tris(3,3,3-trifluoropropyl)-1,3,5,2,4,6-trioxatrisilinane Chemical group FC(F)(F)CC[Si]1(C)O[Si](C)(CCC(F)(F)F)O[Si](C)(CCC(F)(F)F)O1 URZHQOCYXDNFGN-UHFFFAOYSA-N 0.000 description 8
- 229920002367 Polyisobutene Polymers 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 8
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 229940089114 Drug Delivery Device Drugs 0.000 description 6
- 229940072981 Nitro-Dur Drugs 0.000 description 6
- 239000004698 Polyethylene (PE) Substances 0.000 description 6
- NIXOWILDQLNWCW-UHFFFAOYSA-M acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 6
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 6
- 229920000573 polyethylene Polymers 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 5
- 229920001577 copolymer Polymers 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 230000037317 transdermal delivery Effects 0.000 description 5
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 239000003522 acrylic cement Substances 0.000 description 4
- PUPZLCDOIYMWBV-UHFFFAOYSA-N butylene glycol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- 239000004205 dimethyl polysiloxane Substances 0.000 description 4
- 238000011068 load Methods 0.000 description 4
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000009834 vaporization Methods 0.000 description 4
- XTXRWKRVRITETP-UHFFFAOYSA-N vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 4
- JTXMVXSTHSMVQF-UHFFFAOYSA-N 2-acetyloxyethyl acetate Chemical compound CC(=O)OCCOC(C)=O JTXMVXSTHSMVQF-UHFFFAOYSA-N 0.000 description 3
- 229930006677 A03BA01 - Atropine Natural products 0.000 description 3
- RKUNBYITZUJHSG-SPUOUPEWSA-N Atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 3
- 229960000396 Atropine Drugs 0.000 description 3
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-α-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 3
- 102000011782 Keratins Human genes 0.000 description 3
- 108010076876 Keratins Proteins 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 125000005250 alkyl acrylate group Chemical group 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 125000005373 siloxane group Chemical group [SiH2](O*)* 0.000 description 3
- 230000001225 therapeutic Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- QSAVEGSLJISCDF-UHFFFAOYSA-N (1,2,2,6-tetramethylpiperidin-4-yl) 2-hydroxy-2-phenylacetate Chemical compound C1C(C)(C)N(C)C(C)CC1OC(=O)C(O)C1=CC=CC=C1 QSAVEGSLJISCDF-UHFFFAOYSA-N 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 2
- LZCOQTDXKCNBEE-IKIFYQGPSA-N CHEMBL376897 Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)C)=CC=CC=C1 LZCOQTDXKCNBEE-IKIFYQGPSA-N 0.000 description 2
- 229940107080 Chlorpheniramine Drugs 0.000 description 2
- SKYSRIRYMSLOIN-UHFFFAOYSA-N Cyclopentolate Chemical compound C1CCCC1(O)C(C(=O)OCCN(C)C)C1=CC=CC=C1 SKYSRIRYMSLOIN-UHFFFAOYSA-N 0.000 description 2
- SOYKEARSMXGVTM-HNNXBMFYSA-N Dexchlorpheniramine Chemical compound C1([C@H](CCN(C)C)C=2N=CC=CC=2)=CC=C(Cl)C=C1 SOYKEARSMXGVTM-HNNXBMFYSA-N 0.000 description 2
- KWGRBVOPPLSCSI-WPRPVWTQSA-N Ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- 210000002615 Epidermis Anatomy 0.000 description 2
- POPFMWWJOGLOIF-XWCQMRHXSA-N Fludroxycortide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O POPFMWWJOGLOIF-XWCQMRHXSA-N 0.000 description 2
- 229940013644 Flurandrenolide Drugs 0.000 description 2
- 210000003780 Hair Follicle Anatomy 0.000 description 2
- MUQNGPZZQDCDFT-JNQJZLCISA-N Halcinonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@@H]2O MUQNGPZZQDCDFT-JNQJZLCISA-N 0.000 description 2
- ZTVIKZXZYLEVOL-MCOXGKPRSA-N Homatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(O)C1=CC=CC=C1 ZTVIKZXZYLEVOL-MCOXGKPRSA-N 0.000 description 2
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N Indometacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 2
- DLNKOYKMWOXYQA-APPZFPTMSA-N L-Norpseudoephedrine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N Linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- YECBIJXISLIIDS-UHFFFAOYSA-N Mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 2
- GZHFODJQISUKAY-UHFFFAOYSA-N Methantheline Chemical compound C1=CC=C2C(C(=O)OCC[N+](C)(CC)CC)C3=CC=CC=C3OC2=C1 GZHFODJQISUKAY-UHFFFAOYSA-N 0.000 description 2
- 229960002554 Methscopolamine Drugs 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N Methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- VHRSUDSXCMQTMA-PJHHCJLFSA-N Methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 229960001802 Phenylephrine Drugs 0.000 description 2
- SONNWYBIRXJNDC-VIFPVBQESA-N Phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 2
- 229960000395 Phenylpropanolamine Drugs 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N Prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 229940079863 Pyrilamine Drugs 0.000 description 2
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 2
- STECJAGHUSJQJN-FWXGHANASA-N Scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 2
- YYGNTYWPHWGJRM-RUSDCZJESA-N Squalene Natural products C(=C\CC/C(=C\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C)(\CC/C=C(\C)/C)/C YYGNTYWPHWGJRM-RUSDCZJESA-N 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 229960001603 Tamoxifen Drugs 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 229960001295 Tocopherol Drugs 0.000 description 2
- HWKQNAWCHQMZHK-UHFFFAOYSA-N Trolnitrate Chemical compound [O-][N+](=O)OCCN(CCO[N+]([O-])=O)CCO[N+]([O-])=O HWKQNAWCHQMZHK-UHFFFAOYSA-N 0.000 description 2
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 229940046009 Vitamin E Drugs 0.000 description 2
- NAUDKYVGHCCLOT-LAQCMFAESA-N [(8R,9S,10R,13S,14S,17R)-17-ethynyl-13-methyl-3-oxo-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate;(8R,9S,13S,14S,17S)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1.C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 NAUDKYVGHCCLOT-LAQCMFAESA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001253 acrylic acids Chemical class 0.000 description 2
- 239000002998 adhesive polymer Substances 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 229960001452 alpha-Tocopherol Acetate Drugs 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- 229960003291 chlorphenamine Drugs 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 229960001815 cyclopentolate Drugs 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 229950002420 eucatropine Drugs 0.000 description 2
- 229960004511 fludroxycortide Drugs 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 229920000591 gum Polymers 0.000 description 2
- 229960002383 halcinonide Drugs 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 229960000857 homatropine Drugs 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229960000582 mepyramine Drugs 0.000 description 2
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-M methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
- 229960001470 methantheline Drugs 0.000 description 2
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1R,2R,3R)-3-hydroxy-2-[(1E)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 description 2
- 229960004584 methylprednisolone Drugs 0.000 description 2
- 229960005249 misoprostol Drugs 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- 229960003910 promethazine Drugs 0.000 description 2
- 230000001681 protective Effects 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 229960002646 scopolamine Drugs 0.000 description 2
- 230000001624 sedative Effects 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 2
- 231100000245 skin permeability Toxicity 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229920001897 terpolymer Polymers 0.000 description 2
- 239000003451 thiazide diuretic agent Substances 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 229930003799 tocopherols Natural products 0.000 description 2
- 229960004791 tropicamide Drugs 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- AELCINSCMGFISI-DTWKUNHWSA-N (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@@H]1C[C@H]1C1=CC=CC=C1 AELCINSCMGFISI-DTWKUNHWSA-N 0.000 description 1
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 1
- SSMSBSWKLKKXGG-UHFFFAOYSA-N 1-(2-chlorophenyl)-2-(propan-2-ylamino)ethanol Chemical compound CC(C)NCC(O)C1=CC=CC=C1Cl SSMSBSWKLKKXGG-UHFFFAOYSA-N 0.000 description 1
- OZOMQRBLCMDCEG-VIZOYTHASA-N 1-[(E)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(O1)=CC=C1\C=N\N1C(=O)NC(=O)C1 OZOMQRBLCMDCEG-VIZOYTHASA-N 0.000 description 1
- NJPQAIBZIHNJDO-UHFFFAOYSA-N 1-dodecylpyrrolidin-2-one Chemical compound CCCCCCCCCCCCN1CCCC1=O NJPQAIBZIHNJDO-UHFFFAOYSA-N 0.000 description 1
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
- DQJSFBCVEPQRLA-UHFFFAOYSA-N 1-methoxyethyl prop-2-enoate Chemical compound COC(C)OC(=O)C=C DQJSFBCVEPQRLA-UHFFFAOYSA-N 0.000 description 1
- NZJXADCEESMBPW-UHFFFAOYSA-N 1-methylsulfinyldecane Chemical compound CCCCCCCCCCS(C)=O NZJXADCEESMBPW-UHFFFAOYSA-N 0.000 description 1
- PVVATGNFHKTPTA-UHFFFAOYSA-N 1-methylsulfinyloctane Chemical compound CCCCCCCCS(C)=O PVVATGNFHKTPTA-UHFFFAOYSA-N 0.000 description 1
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 description 1
- DPBJAVGHACCNRL-UHFFFAOYSA-N 2-(dimethylamino)ethyl prop-2-enoate Chemical compound CN(C)CCOC(=O)C=C DPBJAVGHACCNRL-UHFFFAOYSA-N 0.000 description 1
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(naphthalen-1-ylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 description 1
- KDAKDBASXBEFFK-UHFFFAOYSA-N 2-(tert-butylamino)ethyl prop-2-enoate Chemical compound CC(C)(C)NCCOC(=O)C=C KDAKDBASXBEFFK-UHFFFAOYSA-N 0.000 description 1
- GOXQRTZXKQZDDN-UHFFFAOYSA-N 2-Ethylhexyl acrylate Chemical compound CCCCC(CC)COC(=O)C=C GOXQRTZXKQZDDN-UHFFFAOYSA-N 0.000 description 1
- YMJMZFPZRVMNCH-FMIVXFBMSA-N 2-[methyl-[(E)-3-phenylprop-2-enyl]amino]-1-phenylpropan-1-ol Chemical compound C=1C=CC=CC=1/C=C/CN(C)C(C)C(O)C1=CC=CC=C1 YMJMZFPZRVMNCH-FMIVXFBMSA-N 0.000 description 1
- JGRXEBOFWPLEAV-UHFFFAOYSA-N 2-ethylbutyl prop-2-enoate Chemical compound CCC(CC)COC(=O)C=C JGRXEBOFWPLEAV-UHFFFAOYSA-N 0.000 description 1
- WDQMWEYDKDCEHT-UHFFFAOYSA-N 2-ethylhexyl 2-methylprop-2-enoate Chemical compound CCCCC(CC)COC(=O)C(C)=C WDQMWEYDKDCEHT-UHFFFAOYSA-N 0.000 description 1
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 1
- YXYJVFYWCLAXHO-UHFFFAOYSA-N 2-methoxyethyl 2-methylprop-2-enoate Chemical compound COCCOC(=O)C(C)=C YXYJVFYWCLAXHO-UHFFFAOYSA-N 0.000 description 1
- KFTHUBZIEMOORC-UHFFFAOYSA-N 2-methylbut-2-enamide Chemical compound CC=C(C)C(N)=O KFTHUBZIEMOORC-UHFFFAOYSA-N 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N 3-hydroxy-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- QZPSOSOOLFHYRR-UHFFFAOYSA-N 3-hydroxypropyl prop-2-enoate Chemical compound OCCCOC(=O)C=C QZPSOSOOLFHYRR-UHFFFAOYSA-N 0.000 description 1
- GIKNHHRFLCDOEU-UHFFFAOYSA-N 4-Hydroxyamphetamine Chemical compound CC(N)CC1=CC=C(O)C=C1 GIKNHHRFLCDOEU-UHFFFAOYSA-N 0.000 description 1
- 150000005011 4-aminoquinolines Chemical class 0.000 description 1
- KQPKPCNLIDLUMF-MRVPVSSYSA-N 5-[(2R)-pentan-2-yl]-5-prop-2-enyl-1,3-diazinane-2,4,6-trione Chemical compound CCC[C@@H](C)C1(CC=C)C(=O)NC(=O)NC1=O KQPKPCNLIDLUMF-MRVPVSSYSA-N 0.000 description 1
- NQSLZEHVGKWKAY-UHFFFAOYSA-N 6-methylheptyl 2-methylprop-2-enoate Chemical compound CC(C)CCCCCOC(=O)C(C)=C NQSLZEHVGKWKAY-UHFFFAOYSA-N 0.000 description 1
- DXPPIEDUBFUSEZ-UHFFFAOYSA-N 6-methylheptyl prop-2-enoate Chemical compound CC(C)CCCCCOC(=O)C=C DXPPIEDUBFUSEZ-UHFFFAOYSA-N 0.000 description 1
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
- 229940074728 ANTIINFECTIVE OPHTHALMOLOGICS Drugs 0.000 description 1
- 229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 description 1
- 229940033495 ANTIMALARIALS Drugs 0.000 description 1
- 229940005529 ANTIPSYCHOTICS Drugs 0.000 description 1
- ZZHLYYDVIOPZBE-UHFFFAOYSA-N Alimemazine Chemical compound C1=CC=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1 ZZHLYYDVIOPZBE-UHFFFAOYSA-N 0.000 description 1
- 229960000458 Allantoin Drugs 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N Aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N Amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 Amantadine Drugs 0.000 description 1
- XXEPPPIWZFICOJ-UHFFFAOYSA-N Amfepramone Chemical compound CCN(CC)C(C)C(=O)C1=CC=CC=C1 XXEPPPIWZFICOJ-UHFFFAOYSA-N 0.000 description 1
- 229960000836 Amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N Amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 229960002519 Amoxapine Drugs 0.000 description 1
- QWGDMFLQWFTERH-UHFFFAOYSA-N Amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 1
- 229940025084 Amphetamine Drugs 0.000 description 1
- 229940005553 Analgesics and anesthetics Drugs 0.000 description 1
- 229940118324 Anisotropine Drugs 0.000 description 1
- REYFJDPCWQRWAA-UHFFFAOYSA-N Antazoline Chemical compound N=1CCNC=1CN(C=1C=CC=CC=1)CC1=CC=CC=C1 REYFJDPCWQRWAA-UHFFFAOYSA-N 0.000 description 1
- 229940088710 Antibiotic Drugs 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 229940021383 Antiinfective irrigating solutions Drugs 0.000 description 1
- 229960005475 Antiinfectives Drugs 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- 229960004046 Apomorphine Drugs 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N Apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 208000006673 Asthma Diseases 0.000 description 1
- 229960000794 Baclofen Drugs 0.000 description 1
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
- IRIAEXORFWYRCZ-UHFFFAOYSA-N Benzyl butyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCC1=CC=CC=C1 IRIAEXORFWYRCZ-UHFFFAOYSA-N 0.000 description 1
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N Benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N Betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229960002802 Bromocriptine Drugs 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N Bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- ZDIGNSYAACHWNL-UHFFFAOYSA-N Brompheniramine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Br)C=C1 ZDIGNSYAACHWNL-UHFFFAOYSA-N 0.000 description 1
- 229940095259 Butylated Hydroxytoluene Drugs 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 229960004205 CARBIDOPA Drugs 0.000 description 1
- XYJQBHCHAZPWHA-UHFFFAOYSA-N CC(C)C([CH2-])=O Chemical compound CC(C)C([CH2-])=O XYJQBHCHAZPWHA-UHFFFAOYSA-N 0.000 description 1
- WKWOJBUWWZTUQV-SPUOUPEWSA-N CHEMBL1201235 Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N+]2(C)C)C(=O)C(O)C1=CC=CC=C1 WKWOJBUWWZTUQV-SPUOUPEWSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N C[N+](C)(C)CCO Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- TZFNLOMSOLWIDK-JTQLQIEISA-N Carbidopa Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 description 1
- OJFSXZCBGQGRNV-UHFFFAOYSA-N Carbinoxamine Chemical compound C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 OJFSXZCBGQGRNV-UHFFFAOYSA-N 0.000 description 1
- HFFLGKNGCAIQMO-UHFFFAOYSA-N Chloral Chemical compound ClC(Cl)(Cl)C=O HFFLGKNGCAIQMO-UHFFFAOYSA-N 0.000 description 1
- 229960005091 Chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N Chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- WFNAKBGANONZEQ-UHFFFAOYSA-N Chlorcyclizine Chemical compound C1CN(C)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 WFNAKBGANONZEQ-UHFFFAOYSA-N 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N Chloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 229960003677 Chloroquine Drugs 0.000 description 1
- 229950011462 Clorprenaline Drugs 0.000 description 1
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N Corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
- JYGXADMDTFJGBT-VWUMJDOOSA-N Cortisol Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- UVKZSORBKUEBAZ-UHFFFAOYSA-N Cyclizine Chemical compound C1CN(C)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 UVKZSORBKUEBAZ-UHFFFAOYSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 229960001987 Dantrolene Drugs 0.000 description 1
- 206010061428 Decreased appetite Diseases 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- 229960003957 Dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229940119750 Dextroamphetamine Drugs 0.000 description 1
- 229940120131 Dicyclomine Drugs 0.000 description 1
- CURUTKGFNZGFSE-UHFFFAOYSA-N Dicycloverine Chemical compound C1CCCCC1C1(C(=O)OCCN(CC)CC)CCCCC1 CURUTKGFNZGFSE-UHFFFAOYSA-N 0.000 description 1
- 229960002777 Dicycloverine Drugs 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N Diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- HESHRHUZIWVEAJ-JGRZULCMSA-N Dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 description 1
- 229960004993 Dimenhydrinate Drugs 0.000 description 1
- MZDOIJOUFRQXHC-UHFFFAOYSA-N Dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N Diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 229940113120 Dipropylene Glycol Drugs 0.000 description 1
- 229960005426 Doxepin Drugs 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N Doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N Epinephrine Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N Esomeprazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- 229940042344 Estradiol / Norethindrone Drugs 0.000 description 1
- JYILPERKVHXLNF-QMNUTNMBSA-N Etynodiol Chemical compound O[C@H]1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 JYILPERKVHXLNF-QMNUTNMBSA-N 0.000 description 1
- 210000000416 Exudates and Transudates Anatomy 0.000 description 1
- ZPAKPRAICRBAOD-UHFFFAOYSA-N Fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 1
- 229960001582 Fenfluramine Drugs 0.000 description 1
- 229960001419 Fenoprofen Drugs 0.000 description 1
- RDJGLLICXDHJDY-UHFFFAOYSA-N Fenoprofen Chemical compound OC(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-UHFFFAOYSA-N 0.000 description 1
- AAXVEMMRQDVLJB-BULBTXNYSA-N Fludrocortisone Chemical compound O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 AAXVEMMRQDVLJB-BULBTXNYSA-N 0.000 description 1
- 229960002011 Fludrocortisone Drugs 0.000 description 1
- UUOUOERPONYGOS-CLCRDYEYSA-N Fluocinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@H](F)C2=C1 UUOUOERPONYGOS-CLCRDYEYSA-N 0.000 description 1
- YLRFCQOZQXIBAB-RBZZARIASA-N Fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
- 229960001751 Fluoxymesterone Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N Flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- 229960003246 Homatropine methylbromide Drugs 0.000 description 1
- 229940084986 Human Chorionic Gonadotropin Drugs 0.000 description 1
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N Hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 229960004716 Idoxuridine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N Imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 229960000905 Indomethacin Drugs 0.000 description 1
- RJMIEHBSYVWVIN-UHFFFAOYSA-N Indoprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1N1C(=O)C2=CC=CC=C2C1 RJMIEHBSYVWVIN-UHFFFAOYSA-N 0.000 description 1
- 206010022114 Injury Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- XKFPYPQQHFEXRZ-UHFFFAOYSA-N Isocarboxazid Chemical compound O1C(C)=CC(C(=O)NNCC=2C=CC=CC=2)=N1 XKFPYPQQHFEXRZ-UHFFFAOYSA-N 0.000 description 1
- AXISYYRBXTVTFY-UHFFFAOYSA-N Isopropyl myristate Chemical compound CCCCCCCCCCCCCC(=O)OC(C)C AXISYYRBXTVTFY-UHFFFAOYSA-N 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N Isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- KLDXJTOLSGUMSJ-JGWLITMVSA-N Isosorbide Chemical compound O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 KLDXJTOLSGUMSJ-JGWLITMVSA-N 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N Ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- SFLSHLFXELFNJZ-MRVPVSSYSA-N L-Noradrenaline Natural products NC[C@@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-MRVPVSSYSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 229940039717 Lanolin Drugs 0.000 description 1
- OYHQOLUKZRVURQ-UHFFFAOYSA-N Linoleic acid Chemical compound CCCCCC=CCC=CCCCCCCCC(O)=O OYHQOLUKZRVURQ-UHFFFAOYSA-N 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N Maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- QSLMDECMDJKHMQ-GSXCWMCISA-N Maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 description 1
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 1
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 1
- 229940041321 Meclizine Drugs 0.000 description 1
- 229940041334 Meclofenamate Sodium Drugs 0.000 description 1
- GZENKSODFLBBHQ-ILSZZQPISA-N Medrysone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@H](C(C)=O)CC[C@H]21 GZENKSODFLBBHQ-ILSZZQPISA-N 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N Mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- HNJJXZKZRAWDPF-UHFFFAOYSA-N Methapyrilene Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CS1 HNJJXZKZRAWDPF-UHFFFAOYSA-N 0.000 description 1
- 229960001869 Methapyrilene Drugs 0.000 description 1
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 206010028334 Muscle spasms Diseases 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N Naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 229960004127 Naloxone Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N Naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- IAIWVQXQOWNYOU-FPYGCLRLSA-N Nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 description 1
- 229960001907 Nitrofurazone Drugs 0.000 description 1
- 229960002748 Norepinephrine Drugs 0.000 description 1
- 229960001158 Nortriptyline Drugs 0.000 description 1
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
- 229940074726 OPHTHALMOLOGIC ANTIINFLAMMATORY AGENTS Drugs 0.000 description 1
- DBGIVFWFUFKIQN-UHFFFAOYSA-N Obedrex Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 1
- 229940082615 Organic nitrates used in cardiac disease Drugs 0.000 description 1
- 229940006000 Other antiinfectives in ATC Drugs 0.000 description 1
- 229940101267 Panthenol Drugs 0.000 description 1
- XQYZDYMELSJDRZ-UHFFFAOYSA-N Papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 1
- MKPDWECBUAZOHP-AFYJWTTESA-N Paramethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O MKPDWECBUAZOHP-AFYJWTTESA-N 0.000 description 1
- 229960002858 Paramethasone Drugs 0.000 description 1
- 206010061536 Parkinson's disease Diseases 0.000 description 1
- 229940049954 Penicillin Drugs 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229960001412 Pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N Pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 229960000964 Phenelzine Drugs 0.000 description 1
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
- 229960001190 Pheniramine Drugs 0.000 description 1
- IJHNSHDBIRRJRN-UHFFFAOYSA-N Pheniramine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=CC=C1 IJHNSHDBIRRJRN-UHFFFAOYSA-N 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N Phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 Phenobarbital Drugs 0.000 description 1
- DHHVAGZRUROJKS-UHFFFAOYSA-N Phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 1
- 229960003562 Phentermine Drugs 0.000 description 1
- 229960002895 Phenylbutazone Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N Piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- FIADGNVRKBPQEU-UHFFFAOYSA-N Pizotifen Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CCC2=C1C=CS2 FIADGNVRKBPQEU-UHFFFAOYSA-N 0.000 description 1
- 229940068199 Pizotyline Drugs 0.000 description 1
- 230000036823 Plasma Levels Effects 0.000 description 1
- 229920002319 Poly(methyl acrylate) Polymers 0.000 description 1
- 229920001748 Polybutylene Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N Prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- WIKYUJGCLQQFNW-UHFFFAOYSA-N Prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 1
- 229960005360 Procyclidine hydrochloride Drugs 0.000 description 1
- VVWYOYDLCMFIEM-UHFFFAOYSA-N Propantheline Chemical compound C1=CC=C2C(C(=O)OCC[N+](C)(C(C)C)C(C)C)C3=CC=CC=C3OC2=C1 VVWYOYDLCMFIEM-UHFFFAOYSA-N 0.000 description 1
- 229960004063 Propylene glycol Drugs 0.000 description 1
- JCRIVQIOJSSCQD-UHFFFAOYSA-N Propylhexedrine Chemical compound CNC(C)CC1CCCCC1 JCRIVQIOJSSCQD-UHFFFAOYSA-N 0.000 description 1
- 229960000786 Propylhexedrine Drugs 0.000 description 1
- 229940082622 Prostaglandin cardiac therapy preparations Drugs 0.000 description 1
- 229940077717 Prostaglandin drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) Drugs 0.000 description 1
- BWPIARFWQZKAIA-UHFFFAOYSA-N Protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 description 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N Pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
- 229960003908 Pseudoephedrine Drugs 0.000 description 1
- WKSAUQYGYAYLPV-UHFFFAOYSA-N Pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N Reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- IOVGROKTTNBUGK-SJCJKPOMSA-N Ritodrine Chemical compound N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(O)C=C1 IOVGROKTTNBUGK-SJCJKPOMSA-N 0.000 description 1
- 229960001634 Ritodrine Drugs 0.000 description 1
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229940031439 Squalene Drugs 0.000 description 1
- 229960002673 Sulfacetamide Drugs 0.000 description 1
- SKIVFJLNDNKQPD-UHFFFAOYSA-N Sulfacetamide Chemical compound CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 SKIVFJLNDNKQPD-UHFFFAOYSA-N 0.000 description 1
- ASWVTGNCAZCNNR-UHFFFAOYSA-N Sulfadimidine Chemical compound CC1=CC(C)=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ASWVTGNCAZCNNR-UHFFFAOYSA-N 0.000 description 1
- 229960002597 Sulfamerazine Drugs 0.000 description 1
- QPPBRPIAZZHUNT-UHFFFAOYSA-N Sulfamerazine Chemical compound CC1=CC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 QPPBRPIAZZHUNT-UHFFFAOYSA-N 0.000 description 1
- 229940032669 Sulfamethazine Drugs 0.000 description 1
- VACCAVUAMIDAGB-UHFFFAOYSA-N Sulfamethizole Chemical compound S1C(C)=NN=C1NS(=O)(=O)C1=CC=C(N)C=C1 VACCAVUAMIDAGB-UHFFFAOYSA-N 0.000 description 1
- 229940032484 Sulfisoxazole Drugs 0.000 description 1
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfizole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 description 1
- 229960000894 Sulindac Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N Sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229960004492 Suprofen Drugs 0.000 description 1
- MDKGKXOCJGEUJW-UHFFFAOYSA-N Suprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-UHFFFAOYSA-N 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 229940064707 Sympathomimetics Drugs 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 229960000351 Terfenadine Drugs 0.000 description 1
- 229960003604 Testosterone Drugs 0.000 description 1
- 229960002180 Tetracycline Drugs 0.000 description 1
- OFVLGDICTFRJMM-WESIUVDSSA-N Tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- BYJAVTDNIXVSPW-UHFFFAOYSA-N Tetrahydrozoline Chemical compound N1CCN=C1C1C2=CC=CC=C2CCC1 BYJAVTDNIXVSPW-UHFFFAOYSA-N 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N Tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- 229960003991 Trazodone Drugs 0.000 description 1
- PHLBKPHSAVXXEF-UHFFFAOYSA-N Trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 1
- URAYPUMNDPQOKB-UHFFFAOYSA-N Triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 1
- 229960002622 Triacetin Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N Triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- HWHLPVGTWGOCJO-UHFFFAOYSA-N Trihexyphenidyl Chemical compound C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 HWHLPVGTWGOCJO-UHFFFAOYSA-N 0.000 description 1
- 229960004479 Trihexyphenidyl Hydrochloride Drugs 0.000 description 1
- 229940035740 Trimeprazine Drugs 0.000 description 1
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N Trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 1
- UFLGIAIHIAPJJC-UHFFFAOYSA-N Tripelennamine Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CC=C1 UFLGIAIHIAPJJC-UHFFFAOYSA-N 0.000 description 1
- CBEQULMOCCWAQT-WOJGMQOQSA-N Triprolidine Chemical compound C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C/CN1CCCC1 CBEQULMOCCWAQT-WOJGMQOQSA-N 0.000 description 1
- 229940029983 VITAMINS Drugs 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 229940021016 Vitamin IV solution additives Drugs 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- QSFKGMJOKUZAJM-JXMYBXCISA-M [(1R,5S)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl] 2-propylpentanoate;bromide Chemical compound [Br-].C1C(OC(=O)C(CCC)CCC)C[C@@H]2CC[C@H]1[N+]2(C)C QSFKGMJOKUZAJM-JXMYBXCISA-M 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- UGAPHEBNTGUMBB-UHFFFAOYSA-N acetic acid;ethyl acetate Chemical compound CC(O)=O.CCOC(C)=O UGAPHEBNTGUMBB-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229960003790 alimemazine Drugs 0.000 description 1
- 229960002734 amfetamine Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001548 androgenic Effects 0.000 description 1
- 230000001539 anorectic Effects 0.000 description 1
- 229960002469 antazoline Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000049 anti-anxiety Effects 0.000 description 1
- 230000000844 anti-bacterial Effects 0.000 description 1
- 230000001430 anti-depressive Effects 0.000 description 1
- 230000003178 anti-diabetic Effects 0.000 description 1
- 230000001833 anti-estrogenic Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000003388 anti-hormone Effects 0.000 description 1
- 230000002924 anti-infective Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000078 anti-malarial Effects 0.000 description 1
- 230000001022 anti-muscarinic Effects 0.000 description 1
- 230000001754 anti-pyretic Effects 0.000 description 1
- 230000002921 anti-spasmodic Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000000840 anti-viral Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 125000004429 atoms Chemical group 0.000 description 1
- 229960001081 benzatropine Drugs 0.000 description 1
- CPFJLLXFNPCTDW-BWSPSPBFSA-N benzatropine mesylate Chemical compound CS([O-])(=O)=O.O([C@H]1C[C@H]2CC[C@@H](C1)[NH+]2C)C(C=1C=CC=CC=1)C1=CC=CC=C1 CPFJLLXFNPCTDW-BWSPSPBFSA-N 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 229940024774 benztropine mesylate Drugs 0.000 description 1
- 229950004580 benzyl nicotinate Drugs 0.000 description 1
- 229960000626 benzylpenicillin Drugs 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229960000725 brompheniramine Drugs 0.000 description 1
- SOGAXMICEFXMKE-UHFFFAOYSA-N butyl 2-methylprop-2-enoate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 description 1
- CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229960000428 carbinoxamine Drugs 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229960004831 chlorcyclizine Drugs 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 230000001713 cholinergic Effects 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 229960001750 cinnamedrine Drugs 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229910052570 clay Inorganic materials 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229960003564 cyclizine Drugs 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- GTBGXKPAKVYEKJ-UHFFFAOYSA-N decyl 2-methylprop-2-enoate Chemical compound CCCCCCCCCCOC(=O)C(C)=C GTBGXKPAKVYEKJ-UHFFFAOYSA-N 0.000 description 1
- FWLDHHJLVGRRHD-UHFFFAOYSA-N decyl prop-2-enoate Chemical compound CCCCCCCCCCOC(=O)C=C FWLDHHJLVGRRHD-UHFFFAOYSA-N 0.000 description 1
- 230000002939 deleterious Effects 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 239000003241 dermatological agent Substances 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960000632 dexamfetamine Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229960004890 diethylpropion Drugs 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- 229960004704 dihydroergotamine Drugs 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- GMSCBRSQMRDRCD-UHFFFAOYSA-N dodecyl 2-methylprop-2-enoate Chemical compound CCCCCCCCCCCCOC(=O)C(C)=C GMSCBRSQMRDRCD-UHFFFAOYSA-N 0.000 description 1
- PBOSTUDLECTMNL-UHFFFAOYSA-N dodecyl prop-2-enoate Chemical compound CCCCCCCCCCCCOC(=O)C=C PBOSTUDLECTMNL-UHFFFAOYSA-N 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-M dodecyl sulfate Chemical class CCCCCCCCCCCCOS([O-])(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-M 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229960003559 enprostil Drugs 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 229960004766 estradiol valerate Drugs 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002195 fatty ethers Chemical class 0.000 description 1
- 229960001395 fenbufen Drugs 0.000 description 1
- 229940043075 fluocinolone Drugs 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- RTIAQOLKVLAEAU-UHFFFAOYSA-N hexan-3-yl acetate Chemical compound CCCC(CC)OC(C)=O RTIAQOLKVLAEAU-UHFFFAOYSA-N 0.000 description 1
- 239000008079 hexane Substances 0.000 description 1
- LNCPIMCVTKXXOY-UHFFFAOYSA-N hexyl 2-methylprop-2-enoate Chemical compound CCCCCCOC(=O)C(C)=C LNCPIMCVTKXXOY-UHFFFAOYSA-N 0.000 description 1
- LNMQRPPRQDGUDR-UHFFFAOYSA-N hexyl prop-2-enoate Chemical compound CCCCCCOC(=O)C=C LNMQRPPRQDGUDR-UHFFFAOYSA-N 0.000 description 1
- 238000007757 hot melt coating Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- UHSXRTHJCJGEKG-UHFFFAOYSA-N hydron;1-[(3,4,5-trimethoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinoline-6,7-diol;chloride Chemical compound Cl.COC1=C(OC)C(OC)=CC(CC2C3=CC(O)=C(O)C=C3CCN2)=C1 UHSXRTHJCJGEKG-UHFFFAOYSA-N 0.000 description 1
- 229950005360 hydroxyamfetamine Drugs 0.000 description 1
- 229960000930 hydroxyzine Drugs 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229960004187 indoprofen Drugs 0.000 description 1
- 239000000077 insect repellent Substances 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- 229960002672 isocarboxazid Drugs 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- 229940075495 isopropyl palmitate Drugs 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 229940049918 linoleate Drugs 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229960004090 maprotiline Drugs 0.000 description 1
- 229960000299 mazindol Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960003803 meclofenamic acid Drugs 0.000 description 1
- 229960001474 meclozine Drugs 0.000 description 1
- 229960001011 medrysone Drugs 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229960001252 methamphetamine Drugs 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- PTOJVMZPWPAXER-VFJVYMGBSA-N methyl 7-[(1R,2R,3R)-3-hydroxy-2-[(E,3R)-3-hydroxy-4-phenoxybut-1-enyl]-5-oxocyclopentyl]hepta-4,5-dienoate Chemical compound O[C@@H]1CC(=O)[C@H](CC=C=CCCC(=O)OC)[C@H]1\C=C\[C@@H](O)COC1=CC=CC=C1 PTOJVMZPWPAXER-VFJVYMGBSA-N 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229960000634 methylhomatropine Drugs 0.000 description 1
- 229960001566 methyltestosterone Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000003547 miosis Effects 0.000 description 1
- 239000003604 miotic agent Substances 0.000 description 1
- 230000003551 muscarinic Effects 0.000 description 1
- 230000002911 mydriatic Effects 0.000 description 1
- 239000002637 mydriatic agent Substances 0.000 description 1
- IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 1
- 229960005016 naphazoline Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- 229940005943 ophthalmologic Antivirals Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940094443 oxytocics Prostaglandins Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 229960001789 papaverine Drugs 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- 229960004572 pizotifen Drugs 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001084 poly(chloroprene) Polymers 0.000 description 1
- 229920001483 poly(ethyl methacrylate) polymer Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920000120 polyethyl acrylate Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001195 polyisoprene Polymers 0.000 description 1
- 150000003097 polyterpenes Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229960003111 prochlorperazine Drugs 0.000 description 1
- ZFSPFXJSEHCTTR-UHFFFAOYSA-N procyclidine hydrochloride Chemical compound [H+].[Cl-].C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCC1 ZFSPFXJSEHCTTR-UHFFFAOYSA-N 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 229960000697 propantheline Drugs 0.000 description 1
- BVWMJLIIGRDFEI-QXMHVHEDSA-N propyl (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCC BVWMJLIIGRDFEI-QXMHVHEDSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000036678 protein binding Effects 0.000 description 1
- 229960002601 protriptyline Drugs 0.000 description 1
- 230000003236 psychic Effects 0.000 description 1
- 229960000611 pyrimethamine Drugs 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 230000000241 respiratory Effects 0.000 description 1
- 150000004609 retinol derivatives Chemical class 0.000 description 1
- 229960000581 salicylamide Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 229960002060 secobarbital Drugs 0.000 description 1
- 229960003946 selegiline Drugs 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N silicate Chemical group [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 230000037335 skin penetration Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- OGPIIGMUPMPMNT-UHFFFAOYSA-M sodium;2-(2,6-dichloro-3-methylanilino)benzoate Chemical compound [Na+].CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C([O-])=O)=C1Cl OGPIIGMUPMPMNT-UHFFFAOYSA-M 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 229960002135 sulfadimidine Drugs 0.000 description 1
- 229960000654 sulfafurazole Drugs 0.000 description 1
- 229960005158 sulfamethizole Drugs 0.000 description 1
- 230000000475 sunscreen Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 230000001975 sympathomimetic Effects 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 229940016284 tetrahydrozoline Drugs 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 229960000337 tetryzoline Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- 229940026754 topical Antivirals Drugs 0.000 description 1
- 229960003741 tranylcypromine Drugs 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- KEROTHRUZYBWCY-UHFFFAOYSA-N tridecyl 2-methylprop-2-enoate Chemical compound CCCCCCCCCCCCCOC(=O)C(C)=C KEROTHRUZYBWCY-UHFFFAOYSA-N 0.000 description 1
- XOALFFJGWSCQEO-UHFFFAOYSA-N tridecyl prop-2-enoate Chemical compound CCCCCCCCCCCCCOC(=O)C=C XOALFFJGWSCQEO-UHFFFAOYSA-N 0.000 description 1
- 229960002431 trimipramine Drugs 0.000 description 1
- 229960003223 tripelennamine Drugs 0.000 description 1
- 229960001128 triprolidine Drugs 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 230000000261 vasodilator Effects 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229930003231 vitamins Natural products 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 150000003738 xylenes Chemical class 0.000 description 1
Description
BOLUBILITY PARAMETER BABED DRUG DELIVERY SYSTEM AND
' METHOD FOR ALTERING DRUG SATURATION CONCENTRATION
' Background og_the Invention
' This invention relates generally to transdermal drug
E delivery systems, and more particularly, to a
i transdermal drug delivery composition wherein a blend
J of polymers is utilized to affect the rate of drug
delivery from the composition. More specifically, a
plurality of polymers having differing solubility
parameters, preferably immiscible with each other,
adjusts the solubility of the drug in a polymeric
adhesive system formed by the blend and modulates the
delivery of the drug from the composition and through
.4 p
the dermis.
The use of a transdermal composition, for example
a pressure-sensitive adhesive containing a medicament,
namely, a drug, as a means of controlling drug
delivery through the skin at essentially a constant
rate, is well known. Such known delivery systems
involve incorporation of a medicament into a carrier
such as a polymeric matrix and/or a pressure—sensitive
adhesive formulation. ‘The pressure-sensitive adhesive
must adhere effectively to the skin and permit
migration of the medicament from the carrier through
the skin and into the bloodstream of the patient.
Many factors influence the design and performance
of sustained or controlled release drug delivery
products, and dermal delivery systems ix: general,
including drug properties, optimum delivery rate,
target site(s), type of therapy (short-term or
chronic), patient compliance, etc. Among the drug
properties which are known to influence the rate of
release or permeation, or both, into the skin are the
physicochemical properties, including molecular size,
shape, and volume; solubilitfl lb3th—inHthé deltve --w
system and through the skin); partitioning
characteristics; degree of ionization; charge; and
protein binding propensity.
when a drug is contained in a carrier, for
example, a pressure-sensitive adhesive for transdermal
delivery, the rate of administration may be affected
by the rate of release of the drug from the carrier,
as well as the rate of passage of the drug through the
skin. These rates vary from drug-to-drug and from
carrier-to-carrier. A variety of mathematical
equations have been proposed in the prior art to
describe theoretically the fundamentals of mass
transfer phenomena involved in diffusion through a
carrier and development of a flux across a membrane
such as the skin.
Transdermal drug delivery systems can be divided
into two general groups: system-controlled and
skin—controlled devices. with skin-controlled
devices, net drug delivery is controlled by the rate
of drug permeation through the skin. Skin-controlled
systems can be further subdivided into monolithic
devices and reservoir devices.
Generally, a monolithic system comprises a drug
dispersed or dissolved in a matrix comprising a
homogeneous polymeric material of, illustratively,
silicone adhesive, silicone rubber, acrylic adhesive,
polyethylene, polyisobutylene, polyvinyl chloride,
nylon, or the like. The drug is dissolved in the
polymeric matrix until its saturation concentration is
reached. Any additional drug remains dispersed within
the matrix. As drug is removed from the surface of
the matrix, more of the drug diffuses out of the
interior in response to the decreased concentration at
the surface. The release rate is therefore not
constant over time, but instead gradually decreases as
the drug concentration decreases.
The flux, or percutaneous absorption rate of
drugs through the skin, is described by Fick's first
law of diffusion:
J = -D(dCm/dx),
where J is the flux in g/cmflsec, D is the diffusion
coefficient of the drug through the skin in cmf/sec,
and dcm/dx is the concentration gradient of active
agent across the skin.
In order to modify the rate of delivery from a
monolithic transdermal device and into the dermis, the
prior art has typically focused on selecting a
specific single—polymer matrix or a blend of soluble
(miscible) polymers. Illustrative examples are the
novel polymers described in U.S. Patent Nos. 4,898,920
and U.S. 4,751,087. There is a need in the art to
modify the rate of delivery while using commercially
available polymer components.
Another common technique for modifying the rate
of drug delivery is the addition of a vehicle or
enhancer to the formulation to increase the solubility
of the drug within the polymer matrix, for example by
adding a co-solvent such as a polyhydric alcohol or by
changing the skin permeability, for example by adding
enhancers such as ethanol. There is a further need to
be able to modulate the delivery of a drug from a
polymer matrix without adding vehicles or enhancers.
There is no example in the prior art of using a
simple blend of adhesive polymers to affect the rate
of drug delivery from a monolithic adhesive-based
transdermal composition. However, U.S. Patent No.
4,814,168, granted March 21, 1989, and a continuation-
in-part thereof, U.S. Patent No. 4,994,267, issued on
February 19, 1991, both assigned to Noven
Pharmaceuticals, Inc., Miami, FL, disclose the use of
a.mu1tipolymer, specifically an ethylene/vinyl acetate
copolymer or an ethylene/vinyl acetate/acrylic
terpolymer, a rubber and a tackifier in a carrier
composition to improve the adhesive properties. The
composition of U.S. Patent No. 4,994,267 further
includes an acrylate polymer in the system for
additional improvement to the adhesive properties.
Drug concentration in a monolithic transdermal
delivery device can vary widely depending on the drug
and polymers used. For example, certain drugs are
effective in low doses and therefore the transdermal
formulation may involve low concentrations, illustra-
tively 5% or less by weight of the medicament in an
adhesive. other drugs, such as nitroglycerin, require
large doses to be effective and the transdermal
formulation therefore may involve high drug
concentrations, approximately between 5 to 40% or more
by weight in an. adhesive. Low’ concentrations of
medicament typically’ do not critically affect the
adhesion, tack, and shear resistance properties of the
adhesive. However, low drug concentrations in the
adhesive can result in difficulties in achieving an
acceptable delivery rate of the medicament. High
concentrations, on the other hand, frequently affect
the adhesion properties of the adhesives. The
deleterious effects are particularly exacerbated by
drugs which also act as plasticizersor solvents for
the polymeric adhesive material (e.g., nitroglycerin
in polyacrylates).
There is a need in the art for an adhesive
composition for transdermal delivery systems which can
selectably incorporate low concentrations of drug and
deliver same at an adequate and controlled rate or
incorporate high concentrations of drugs while
retaining good physical adhesive properties.
It is, therefore, an object of this invention to
provide a transdermal drug delivery system wherein the
rate of drug delivery from the transdermal composition
may be selectably modulated.
It is another object of this invention to provide
a transdermal drug delivery system wherein the rate of
drug delivery from the transdermal composition may be
selectably modulated by adjusting the solubility
and/or diffusivity of the drug in the multiple polymer
adhesive system.
It is also an object of this invention to provide
a transdermal drug delivery system wherein the
multiple polymer adhesive system is simple to
manufacture.
It is a further object of this invention to
provide a transdermal drug delivery system wherein
drug-loading of a multiple polymer adhesive system may
be selectably varied without adverse effects on drug
delivery rate and adhesive properties, such as
adhesion, tack, and shear resistance.
It is additionally an object of this invention to
provide a transdermal drug delivery system wherein a
novel multiple polymer adhesive system is provided
which has desirable physical properties.
fiummary Qf Inyentign
The foregoing and other objects are achieved by
this invention which provides a transdermal drug
delivery system wherein a blend of at least two
polymers having differing solubility parameters
adjusts the solubility of a drug in the polymeric
blend and thereby modulates the delivery of the drug
from the system and through the dermis.
In accordance with a composition aspect of the
invention, an improved. pressure-sensitive adhesive
composition of the type which is suitable as a matrix
for controlled release of a bioactive agent therefrom
comprises a blend of a first polymeric adhesive
material having a first solubility parameter and a
second polymeric adhesive material having a second
solubility parameter, the first and second solubility
parameters being different from one another. The
blend, therefore, has a characteristic net solubility
parameter. In embodiments incorporating a bioactive
agent in the improved pressure-sensitive adhesive
composition, the characteristic net solubility
parameter can be preselected to adjust the saturation
concentration of a bioactive agent in the composition
and thereby control the release of the bioactive
agent. The saturation concentration of the bioactive
agent may be adjusted either upward or downward
depending upon whether the rate of release is to be
enhanced or retarded.
In preferred embodiments, the bioactive agent may
comprise a drug. In particularly, preferred
embodiments, the drug is a steroid, such as an
estrogen cu: a progestational agent, or combination
thereof. In other preferred embodiments, the drug may
be a B1-adrenergic agonist, such as albuterol, or a
cardioactive agent, such as nitroglycerin. In still
other embodiments, the bioactive agent is a
cholinergic agent, such as pilocarpine, or an
antipsychotic such as haloperidol or a
tranquilizer/sedative such as alprazolam.
The pressure-sensitive adhesive composition may
further include enhancers, fillers, co—solvents, and
excipients as are known in the art for use in such
compositions.
In a preferred embodiment of the improved
pressure-sensitive adhesive, the first polymeric
adhesive material is a polyacrylate and the second
adhesive material is a polysiloxane. The polyacrylate
is preferably present in the pressure-sensitive
adhesive composition in an amount ranging from about
2-96% by weight and the polysiloxane is present in an
amount ranging from about 98-4%. Preferably, the
ratio of polyacrylate to polysiloxane is from about
2:98 to about 96:4, and more preferably from about
2:98 to about 86:14 by weight.
In a dermal adhesive composition embodiment of
the invention, a multiple polymer adhesive system
consisting essentially of a blend of 2-96% by weight
of an acrylate polymer and 98-4% by weight of a
polymer of siloxane, the multiple polymer adhesive
system being in an amount of about 99-50% by weight of
the dermal adhesive composition. This is combined with
a bioactive agent in the amount of 0.3-50% by weight
of the total dermal adhesive composition. Optional
additives, such as co-solvent for the bioactive agent
(up to 30% by weight) and enhancers (up to 20% by
weight) may be included in the dermal adhesive
composition.
In a transdermal drug delivery device embodiment,
the improved pressure-sensitive adhesive of the
present invention is combined. with a drug. The
transdermal drug delivery device may comprise a
monolithic adhesive matrix device in some embodiments.
of course, the transdermal drug delivery device may
include a backing material and a release liner as is
known in the art.
The saturation concentration of 21 drug in a
transdermal drug delivery device of the type having a
drug-containing pressure-sensitive adhesive diffusion
matrix is adjusted in accordance with a method aspect
of the present invention by blending at least two
polymers having differing solubility parameters to
form a pressure-sensitive adhesive diffusion matrix
having a net solubility parameter which modifies the
delivery rate of the a drug from the pressure-
sensitive adhesive diffusion matrix and through the
dermis.
Brief Description of the Drawing
Comprehension of the invention is facilitated by
reading the following detailed description, in
conjunction with the annexed drawing, in which:
is a schematic illustration of a
monolithic transdermal drug delivery device of the
present invention;
is a graphic representation of the steady-
state nitroglycerin flux rates through cadaver skin in
vitro from a transdermal drug delivery composition_of
the present invention (formulation of Example 1) and
two commercially-available nitroglycerin-containing
transdermal. delivery’ devices: Transderm-Nitro® (a
trademark of Ciba-Geigy corporation, Summit, NJ), and
Nitro—DurO (a trademark of Key Pharmaceuticals, Inc.,
Kenilworth, NJ);
is a graphical representation which
summarizes in vitro nitroglycerin flux results through
cadaver skin for the polymeric systems of Examples 2-
. The composition of Example 2 (polyacry1ate—only
adhesive) is compared to the multiple polymer
compositions of Examples 3, 4, and 5, in which the
polyacrylate is blended with 21 polyethylene vinyl
acetate, a polyisobutylene, and a polysiloxane,
respectively;
is a graphical representation of the
steady-state nitroglycerin flux through cadaver skin
in vitro from a multiple polymer transdermal adhesive
system of Example 6 comprising various weight ratios
of polyacrylate and polysiloxane;
is a graphical representation of steady-
state estradiol flux through cadaver skin in vitro
from the drug delivery systems of the prior art,
specifically single polymeric adhesives of silicone
and acrylic, as compared to a multiple polymer
t r a n s d e r m a l a d h e s i v e s y s t e m
(polyacrylate/polysiloxane) of the present invention;
is a graphical representation of average
estradiol flux through cadaver skin in vitro from 0 to
22 hours and from 22 to 99 hours for a multiple
polymer transdermal adhesive system comprising various
weight ratios of polyacrylate and polysiloxane;
is a graphical representation of steady-
state norethindrone acetate flux through cadaver skin
in vitro from the drug delivery systems of the prior
art, specifically single polymeric adhesives of
silicone and acrylic, as compared to a multiple
polymer transdermal adhesive system
(polyacrylate/polysiloxane) of the present invention;
is a graphical representation of average
estradiol and norethindrone acetate flux through
cadaver skin in vitro for a multiple polymer
transdermal adhesive system comprising both drugs and
various weight ratios of polyacrylate and
polysiloxane;
is a graphical representation showing the
ratio of average estradiol to norethindrone acetate
flux (estradiol flux divided by norethindrone acetate
flux) through cadaver skin in vitro for a multiple
polymer transdermal adhesive system comprising various
weight ratios of polyacrylate and polysiloxane;
is a graphical representation of steady-
state flux of pilocarpine through cadaver skin in
vitro from the drug delivery systems of the prior art,
specifically single polymeric adhesives of silicone
and acrylic, as compared to a multiple polymer
t r a n s d e r m a 1 a d h e s i v e s y s t e m
(polyacrylate/polysiloxane) of the present invention;
is a graphical representation of steady-
state albuterol and nitroglycerin flux through cadaver
skin in vitro from multiple polymer transdermal
adhesive systems (polyacrylate/polysiloxane) of the
present invention (Examples 24 — 27), and Nitro—Dur®,
respectively;
is a graphical representation of steady-
state estradiol flux through cadaver skin in vitro
from two different multiple polymer transdermal
adhesive systems polyacrylate/ polysiloxane and
polyacrylate/polybutylene;
FIGS. 13 and 14 show the relationship of flux
rate (J) plotted against apparent diffusion
coefficient (D) and net solubility parameter (SP),
respectively, for Compositions I—VI of Example 6. The
net solubility parameter, SP“, was calculated using a
weighted average of the solubility parameters of the
individual polymers comprising the matrix:
sp,,, = ¢,,sp,, + ¢,_sp,_,
where 0" is the weight percentage of polysiloxane and
SP" is the solubility parameter of polysiloxane. The
subscript "pa" refers to the polyacrylate; and
is a plot of diffusion coefficient versus
net solubility parameter.
Detailed Qescription
In one aspect of the present invention, a
pressure-sensitive adhesive composititwa is provided
which comprises a blend of at least two polymers. The
blend of at least two polymers is herein referred to
as a umltiple polymer adhesive system. The term
"blend" is used herein to mean that there is no, or
substantially no, chemical reaction or cross-linking
(other than simple H-bonding) between the polymers in
the multiple polymer adhesive system.
In another aspect of the invention, a controlled
release dermal composition comprises a drug, or other
bioactive agent, in combination with the multiple
polymer adhesive system. In this aspect, the multiple
polymer adhesive not only functions as a carrier
matrix for the drug, but enhances the rate of release
of the drug, and hence the transdermal permeation
rate. In some embodiments of the invention, however,
the multiple polymer adhesive system will function to
retard the transdermal permeation rate.
The invention is premised on the discovery that
the transdermal permeation rate of a drug from the
multiple polymer adhesive system can be selectively
modulated by adjusting the solubility of the drug in
the device. As used herein, the term "transdermal
permeation rate" means the rate of passage of the drug
through the skin; which, as known in the art, may or
may not be affected by the rate of release of the drug
from the carrier.
The polymers comprising the multiple polymer
adhesive system are inert to the drug, and are
preferably immiscible with each other. Forming a
blend of multiple polymers results in an adhesive
system having a characteristic "net solubility
parameter," the selection of which advantageously
permits a selectable modulation of the delivery rate
of the drug by adjusting the solubility of the drug in
the multiple polymer adhesive system.
solubility parameter, also referred to herein as
"SP", has been defined as the sum of all the
intermolecular attractive forces, which are
empirically related.to the extent of mutual solubility
of many chemical species. A general discussion of
solubility parameters is found in an article by
Vaughan, "Using' Solubility’ Parameters in. Cosmetics
Formulation," Q; ggg; Cgsmeg, Chem., Vol.36, pages
319-333 (1985). Many methods have been developed for
the determination of solubility parameters, ranging
from theoretical calculations to totally empirical
correlations. The most convenient method is
Hildebrand's method, which computes the solubility
parameter from molecular weight, boiling point and
density data, which are commonly available for many
materials and which yields values which are usually
within the range of other methods of calculation:
SP = (AEV/V)”.
where V = molecular weight/density and AE, = energy of
vaporization.
Alternatively written, sp = (AH,/v — RT/V) "1
where AI-L, = heat of vaporization, R = gas constant, and
T is the absolute temperature, °I(. For materials,
such as high molecular weight polymers, which have
vapor pressures too low to detect, and thus for which
AB, is not available, several methods have been
developed which use the summation of atomic and group
contributions to 41-1,,
AHV = Bi Ah“
where Ah, is the contribution of the ith atom or group
to the molar heat of vaporization. one convenient
method has been proposed by R. F. Fedors, gL
Engineering and Science, Vol. 14, p. 147 (1974). In
this method AE., and V are be obtained by simply
assuming that
AEV = 2, Aei and V = 2, vi, where Aei and v, are
the additive atomic and group contributions for the
energy of vaporization and molar volume, respectively.
Yet another method of calculating the solubility
parameter of a material is described by Small, J.
Applied E. Vol. 3, p. 71 (1953).
Table I-A below sets forth solubility parameters
of some exemplary adhesive polymers which would be
useful in the practice of the invention and shows the
variation of SP with molecular weight, free -01! and -
C001-I groups, the degree of cross-linking. Table IA is
in (cal/cm’)'” and (J/cm3)"’ as calculated by Small's
method.
TABLE In
golggerg
Addigion pglggers of unsaturaged ester:
Polymethyl mathacrylate
Polyethylmethacrylate
Polymethylacrylate
Polyethylacrylate
ggdggcarban pglggerg
Polyethylene
Polystyrene
Polyiaobutylene
Polyisoprene
Polybutadlene
Polyethylene/butylene
Halo en- ontain n 1 er
Polytetrafluoroethylene
Polyvlnylchlorlda
Polyvlnylldene chloride
Polychloroprene
Polyacrylonitrile
densa on er
Nylon -6.6
Epon resin 1004 (epoxy)
Polzslloxaneg
Polydlmethylailoxane
Cogglzgarg
Polybutadiane-co—acry1onitr119:
75/25 to 70/30
Polybutadlene—co—styrene2
75/25 to 72/28
exoerpwd from Kama‘ Tbcrmopludc Rubber
Shell Chemical Co. Product Brochure Number SC: 193-89
§o1ub11itx Earggeter
(cnllcg)
‘fllCfl|
19.0
18.6
19.8
18.8
16.6
18.6
.7
16.6
16.6
16.2
12.7
19.4
24.9
19.2
26.0
27.8
19.8
14.9
18.9
17.4
Table 1-8 below sets forth solubility parameters calculated
by Fedora‘ method and are expressed in units of (J/cmU'”.
TABLE I-B
Qompggggtg S bil t ram t W
polyethylene/vinyl acetate (40i VAC) 20.9
polydlmethyleiloxane 15.1
polyisobutylene 17.6
E\L*E|.v";'K|I‘-V’&':'|"l‘~) 17.6
3»:-I ‘_.'-.'-'..h‘,"I :r.at'. '."..‘u‘ r’ '1' F .1!‘ -.’- 19. 8
i:--':','4-l,}\y': .-u‘z'_/l=\".\‘.— 20.9
301“/mu! hyl .1v.::“J";n!.e 21.7
.L>olymeI.h'_/1 :nn:L1‘;.\-:1‘,'1.x*.,«;- 22. 3
polystyrene 22.5
nitroglycerin 27.0
estradiol 24.5
norethindrone acetate 21.3
pilocarpine 22.9
albuterol 26.7
In accordance with the principles of the
invention, the transdermal permeation rate is
controlled by varying the polymer components of the
multiple polymer adhesive system so as to alter the
difference in the solubility parameter of the multiple
polymer adhesive system relative to that of the drug
(see Examples 2-5, or 28 and 29, hereinbelow).
Preferably the solubility parameters of the polymer
components are different from one another by an
increment of at least 2 (J/cmfi“3 Most preferably
they differ by at least 4 (J/cm’)‘”.
The transdermal permeation rate is also
controlled by varying the relative proportions of the
polymers comprising the multiple polymer adhesive
system (see Example 6 hereinbelow).
The multiple polymer adhesive system is
preferably formulated so that it is a pressure-
sensitive adhesive at room temperature and has other
desirable characteristics for adhesives used in the
transdermal drug delivery art; such characteristics
include good adherence to skin, ability to be peeled
or otherwise removed without substantial trauma to the
skin, retention of tack with aging, etc. In general,
the multiple polymer adhesive system should have a
glass transition temperature (lg), measured using a
differential scanning calorimeter, of between about
-70° C to 0° C.
Selection of the particular polymer composition
is governed in large part by the drug to be
incorporated in the device, as well as the desired
rate of delivery of the drug. Those skilled in the
art can readily determine the rate of delivery of
drugs from the multiple polymer transdermal adhesive
system in order to select suitable combinations of
polymers and drug for a particular application.
Various techniques can be used to determine the rate
of delivery of the drug from the polymer.
Illustratively, the rate of delivery can be determined
by measuring the transfer of drug from one chamber to
another through cadaver skin over time, and
calculating, from the obtained data, the drug delivery
or flux rate.
In a particularly preferred embodiment of the
invention, the multiple polymer adhesive system
comprises a blend of an acrylic pressure-sensitive
adhesive and a silicone pressure-sensitive adhesive.
The acrylic—based polymer and silicone-based polymer
are preferably in a ratio by weight, respectively,
from about 2:98 to about 96:4, more preferably from
about 2:98 to about 90:10, and even more preferably
about 2:98 to about 86:14. The amount of acrylic-
based polymer (hereinafter referred to broadly as a
polyacrylate) and silicone-based polymer (hereinafter
referred to broadly as a polysiloxane) is selected to
modify the saturation concentration of the drug in the
multiple polymer adhesive system in order to affect
the rate of delivery of the drug from the system and
through the skin.
The adjustment to the saturation concentration of
the drug in the multiple polymer adhesive system can
either be an increase or a decrease. It has been
found that when a polyacrylate having a solubility
parameter SP of about 21 (J/cm’)"’ is used as the
principal polymer of a nitroglycerin (SP about 27
(J/cm3)“’) monolithic system, a significant increase in
the transdermal permeation rate of nitroglycerin can
be achieved by the addition of a polymer having a
lower solubility parameter, for example a polysiloxane
(SP about 15 (J/cm3)‘”). By reducing the "net"
solubility parameter of the multiple polymer
transdermal adhesive system, the difference between
the solubility parameter of nitroglycerin and the
multiple polymer adhesive system is increased. This
increased solubility parameter difference, results in
a lower saturation concentration for nitroglycerin,
and thereby a greater thermodynamic driving force.
Conversely, the composition of the multiple polymer
adhesive system can be selected so that the saturation
concentration of the drug in the system is increased,
so the rate of delivery is retarded, such as would be
desirable for administration of scopolamine.
Advantageously, the method and composition of the
present invention permit selectable loading of the
drug in the transdermal drug delivery system. The
concentration by weight of the drug in the dermal
composition is preferably about 0.3 to about 50
percent, more preferably about 0.5 to about 40
percent, and even more preferably about 1.0 to about
percent. Irrespective of whether there is high-
loading or low-loading of the drug into the dermal
composition, the multiple polymer adhesive system of
the presemt invention can be formulated to maintain
acceptable shear, tack, and peel adhesive properties.
Although not wishing to be bound by theory,
particularly in this case where the structure of the
compositicm has not been analyzed, it is postulated
that the polymers of varying solubility parameters,
for example, the polysiloxane and the polyacrylate,
result in a heterogenous mix, with the components of
the polymeric mixture performing as a mutually
interpenetrating polymeric network in the composition.
In other words, the multiple polymer adhesive system
is a mix:t1.1re of essentially mutually insoluble or
immiscible polymers, in contradistinction to the
typical prior art transdermal drug delivery systems
derived from a single polymer or a solution of
mutually soluble polymers.
In the practice of the preferred embodiment of
the invention, the acrylic-based polymer can be any of
the homapolymers, copolymers, terpolymers, and the
like of various acrylic acids. In such preferred
embodiments, the acrylic-based polymer constitutes
preferably from about 2% to about 95% of the total
weight of the total dermal composition, and preferably
about 2% to about 90%, and more preferably about 2% to
about 85%, the amount of acrylate polymer being
dependent on the amount and type of drug used.
The acrylate polymers of this invention are
polymers of one or more monomers of acrylic acids and
other copolymerizable monomers. The acrylate polymers
also include copolymers of alkyl acrylates and/or
methacrylates and/or copolymerizable secondary
monomers or monomers with functional groups. By
varying the amount of each type of monomer added, the
cohesive properties of the resulting acrylate polymer
can be changed as is known in the art. In general,
the acrylate polymer is composed of at least 50% by
weight of an acrylate or alkyl acrylate monomer, from
0 to 20% of a functional monomer copolymerizable with
the acrylate, and from 0 to 40% of other monomers.
Acrylate monomers which can be used include
acrylic acid, methacrylic acid, butyl acrylate, butyl
methacrylate, hexyl acrylate, hexyl methacrylate,
2-ethylbutyl acrylate, 2—ethy1butyl methacrylate,
isooctyl acrylate, isooctyl methacrylate,
2-ethylhexyl acrylate, 2-ethylhexyl methacrylate,
decyl acrylate, decyl methacrylate, dodecyl acrylate,
dodecyl methacrylate, tridecyl acrylate, and tridecyl
methacrylate.
Functional monomers, copolymerizable with. the
above alkyl acrylates or methacrylates, which can be
used include acrylic acid, methacrylic acid, maleic
acid, maleic anhydride, hydroxyethyl acrylate,
hydroxypropyl acrylate, acrylamide, dimethyl-
acrylamide, acrylonitrile, dimethylaminoethyl
acrylate, dimethylaminoethyl methacrylate,
tert-butylaminoethyl acrylate, tert—buty1aminoethy1
methacrylate, methoxyethyl acrylate and methoxyethyl
methacrylate.
Further details and examples of acrylic adhesives
which are suitable in the practice of the invention
are described in Satas, "Acrylic Adhesives," Handbook
of Pressure-Sensitive Adhesive Technolodv. 2nd ed.,
pp. 396-456 (D. Satas, ed.), Van Nostrand Reinhold,
New York (1989).
Suitable acrylic adhesives are commercially
available and include the polyacrylate adhesives sold
under the trademarks Duro—Tak 80-1194, Duro—Tak
80-1196, and Duro-Tak 80-1197 by National starch and
Chemical Corporation, Bridgewater, New Jersey.
Suitable polysiloxanes include silicone
pressure-sensitive adhesives which are based on two
major components: a polymer, or gum, and a tackifying
resin. The polysiloxane adhesive is usually prepared
by cross-linking the gum, typically a high molecular
weight polydiorganosiloxane, with the resin, to
produce a three-dimensional silicate structure, via a
condensation reaction in an appropriate organic
solvent. The ratio of resin to polymer is the most
important factor which can be adjusted in order to
modify the physical properties of polysiloxane
adhesives. Sobieski, et al., "Silicone Pressure
Sensitive Adhesives," nd ok ss e~ ensit e
Adhesive 'Le_c=hno_1o;ty. _2nc1_ed_.., pp- 508-517 (D- Satas.
ed.), Van Nostrand Reinhold, New York (1989).
Further details and examples of silicone pressure
sensitive adhesives which are useful in the practice
of this invention are described in the following U.S.
Patents: 4,591,622; 4,584,355; 4,535,336; and
4,655,767.
Suitable silicone pressure-sensitive adhesives
are commercially available and include the silicone
adhesives sold under the trademarks BIO-PSA X7-3027,
BIO-PSA X7-4919, BIO-PSA X7-2685, and BIO-PSA X7-3122
by Dow Corning Corporation, Medical Products, Midland,
Michigan. BIO-PSA-3027 is particularly suitable for
use in formulations containing amine-functional drugs,
such as albuterol.
In the practice of a preferred embodiment of the
invention, the polysiloxane constitutes preferably
from about 4% to about 97% of the total weight of the
total dermal composition, and preferably about 8% to
about 97%, and more preferably about 14% to about 97%.
In practicing the invention, any bioactive agent
may be included in the dermal composition.
Illustratively the bioactive agent is a drug. Any
drug which is capable of producing a pharmacological
response, localized or systemic, irrespective of
whether therapeutic, diagnostic, or prophylactic in
nature, in plants or animals is within the
contemp1ation.of the invention. In addition to drugs,
bioactive agents such as pesticides, insect
repellents, sun screens, cosmetic agents, etc. are
within the contemplation of the invention. It should
be noted that the bioactive agents may be used singly
or as a mixture of two or more such agents, and in
amounts sufficient to prevent, cure, diagnose or treat
a disease, as the case may be.
Exemplary active drugs that can be administered
by the novel transdermal drug delivery system of this
invention include, but are not limited to:
1. Cardioactive medications, illustratively,
organic nitrates such as nitroglycerin, isosorbide
dinitrate, and isosorbide mononitrates; quinidine
sulfate; procainamide; thiazides such as bendrof1ume-
thiazide, chlorothiazide, and hydrochlorothyazide;
nifedipine; nicardipine; adrenergic blocking agents,
such as timolol and propranolol; verapamil; diltiazem;
captopril; clonidine and prazosin.
2. Androgenic steroids, such as testosterone,
methyltestosterone and fluoxymesterone.
3. Estrogens, such as conjugated estrogens,
esterified estrogens, estropipate, 173 estradiol, 176-
estradiol valerate, equilin, mestranol, estrone,
estriol, 17fl—ethiny1 estradiol, and
diethylstilbestrol.
4 . Progestational agents, such as progesterone,
19-norprogesterone, norethindrone, norethindrone
acetate, melengestrol, chlormadinone, ethisterone,
medroxyprogesterone acetate, hydroxyprogesterone
caproate, ethynodiol diacetate, norethynodrel, 17a
hydroxyprogesterone, dydrogesterone, dimethisterone,
ethinylestrenol, norgestrel, demegestone,
promegestone, and megestrol acetate.
. Drugs having an action on the central
nervous system, for‘ example sedatives, hyponotics,
antianxiety agents, analgesics and anesthetics, such
as chloral, buprenorphine, naloxone, haloperidol,
fluphenazine, pentobarbital, phenobarbital,
secobarbital, codeine, lidocaine, tetracaine,
dyclonine, dibucaine, cocaine, procaine, mepivacaine,
bupivacaine, etidocaine, prilocaine, benzocaine,
fentanyl, and nicotine.
6. Nutritional agents, such as vitamins,
essential amino acids and essential fats.
7. Anti-inflammatory agents, such as
hydrocortisone, cortisone, dexamethasone,
fluocinolone, triamcinolone, medrysone, prednisolone,
flurandrenolide, prednisone, halcinonide, methyl-
prednisolone, flurandrenolide, prednisone,
halcinonide, methylprednisolone, fludrocortisone,
corticosterone, paramethasone, betamethasone,
ibuprophen, naproxen, fenoprofen, fenbufen,
flurbiprofen, indoprofen, ketoprofen, suprofen,
indomethacin, piroxicam, aspirin, salicylic acid,
diflunisal, methyl salicylate, phenylbutazone,
sulindac, mefenamic acid, meclofenamate sodium,
tolmetin, and the like.
8. Antihistamines, such as diphenhydramine,
dimenhydrinate, perphenazine, triprolidine,
pyrilamine, chlorcyclizine, promethazine,
carbinoxamine, tripelennamine, brompheniramine,
hydroxyzine, cyclizine, meclizine, clorprenaline,
terfenadine, and chlorpheniramine.
9. Respiratory agents, such as theophilline and
fl,—adrenergic agonists such as albuterol, terbutaline,
metaproterenol, ritodrine, carbuterol, fenoterol,
quinterenol, rimiterol, solmefamol, soterenol, and
tetroquinol.
. Sympathomimetics, such as dopamine,
norepinephrine, phenylpropanolamine, phenylephrine,
pseudoephedrine, amphetamine, propylhexedrine and
epinephrine.
11. Miotics, such as pilocarpine, and the like.
12. Cholinergic agonists, such as choline,
acetylcholine, methacholine, carbachol, bethanechol,
pilocarpine, muscarine, and arecoline.
13. Antimuscarinic or muscarinic cholinergic
blocking agents such as atropine, scopolamine,
homatropine, methscopolamine, homatropine
methylbromide, methantheline, cyclopentolate,
tropicamide,propantheline,anisotropine,dicyclomine,
and eucatropine.
14. Mydriatics, such as atropine,
cyclopentolate,homatropine,scopo1amine,tropicamide,
eucatropine and hydroxyamphetamine.
. Psychic energizers such as
3-(2-aminopropy1)indo1e, 3-(2—aminobuty1)indo1e, and
the like.
16. Anti-infectives, such as antibiotics,
including penicillin, tetracycline, chloramphenicol,
sulfacetamide, sulfamethazine, sulfadiazine,
sulfamerazine, sulfamethizole and sulfisoxazole;
antivirals, including idoxuridine; antibacterials,
such as erythromycin and clarithromycin; and other
anti-infectives including nitrofurazone and the like.
17. Dermatological agents, such as vitamins A
and E.
18. Humoral agents, such as the prostaglandins,
natural and synthetic, for example PGE,, PGE,a, and
PGF2a, and the PGE, analog misoprostol.
19. Antispasmodics, such as atropine,
methantheline, papaverine, cinnamedrine, and
methscopolamine.
. Antidepressant.drugs, such as isocarboxazid,
phenelzine, tranylcypromine, imipramine,
amitriptyline, trimipramine, doxepin, desipramine,
nortriptyline, protriptyline, amoxapine, maprotiline,
and trazodone.
21. Anti-diabetics, such as insulin, and anti-
cancer drugs such as tamoxifen and methotrexate.
22. Anorectic drugs, such as dextroamphetamine,
methamphetamine, phenylpropanolamine, fenfluramine,
diethylpropion, mazindol, and phentermine.
23. Anti—a11ergenics, such as antazoline,
methapyrilene, chlorpheniramine, pyrilamine and
pheniramine.
24. Tranquilizers, such as reserpine,
chlorpromazine, and antianxiety benzodiazepines such
as alprazolam, chlordiazepoxide, clorazeptate,
halazepam, oxazepam, prazepam, clonazepam, flurazepam,
triazolam, lorazepam and diazepam.
. Antipsychotics, such as thiopropazate,
chlorpromazine, triflupromazine, mesoridazine,
piperacetazine, thioridazine, acetophenazine,
fluphenazine, perphenazine, trifluoperazine,
chlorprathixene, thiothixene, haloperidol,
bromperidol, loxapine, and molindone.
26. Decongestants, such as phenylephrine,
ephedrine, naphazoline, tetrahydrozoline.
27. Antipyretics, such as aspirin, salicylamide,
and the like.
28. Antimigrane agents, such as
dihydroergotamine and pizotyline.
29. Drugs for treating nausea and vomiting, such
as chlorpromazine, perphenazine, prochlorperazine,
promethazine, triethylperazine, triflupromazine, and
trimeprazine.
. Anti-malarials, such as the
4-aminoquinolines,a-aminoquinolines,chloroquine,and
pyrimethamine.
31. Anti-ulcerative agents, such as misoprostol,
omeprazole, and enprostil.
32. Peptides, such as growth releasing factor.
33. Drugs for Parkinson's disease, spasticity,
and acute muscle spasms, such as levodopa, carbidopa,
amantadine, apomorphine, bromocriptine, selegiline
(deprenyl),trihexyphenidylhydrochloride,benztropine
mesylate, procyclidine hydrochloride, baclofen,
diazepam, and dantrolene.
34. Anti—estrogen or hormone agents, such as
tamoxifen or human chorionic gonadotropin.
The active agents can be present in the
composition in different forms, depending on which
form yields the optimum delivery characteristics.
Thus, in the case of drugs, the drug can be in its
free base or acid form, or in the form of salts,
esters, or any other pharmacologically acceptable
derivatives, or as components of molecular complexes.
The amount of drug to be incorporated in the
composition varies depending on the particular drug,
the desired therapeutic effect, and the time span for
which the device is to provide therapy. For most
drugs, the passage of the drugs through the skin will
be the rate—limiting step in delivery. Thus, the
amount of drug and the rate of release is typically
selected so as to provide transdermal delivery
characterized by a zero order time dependency for a
prolonged period of time. The minimum amount of drug
in the system is selected based on the amount of drug
which passes through the skin in the time span for
which the device is to provide therapy. Normally, the
amount of drug in the system can vary from about 0.3%
to about 50% by weight, and preferably, for the lower
drug doses permitted by this invention, from about
1.0% to about 30%.
of course, the composition of the transdermal
drug delivery system can also contain agents known to
accelerate the delivery of the drug through the skin.
These agents have been referred to as skin-penetration
enhancers, accelerants, adjuvants, and sorption
promoters, and are collectively referred herein as
"enhancers." This class of agents includes those with
diverse mechanisms of action including those which
have the functixn1 of improving the solubility and
diffusibility of the drug within the multiple polymer
and those which improve percutaneous absorption, for
example, by changing the ability of the stratum
corneum to retain moisture, softening the skin,
improving the skin's permeability, acting as
penetration assistants or hair-follicle openers or
changing the state of the skin including the boundary
layer. some of these agents have more than one
mechanism of action, but in essence they serve to
enhance the delivery of the drug.
Some examples of enhancers are polyhydric
alcohols such as dipropylene glycol, propylene glycol,
and polyethylene glycol which enhance drug solubility;
oils such as olive oil, squalene, and lanolin; fatty
ethers such as cetyl ether and oleyl ether; fatty acid
esters such as isopropyl myristate which enhance drug
diffusibility; urea and urea derivatives such as
allantoin which affect the ability of keratin to
retain moisture; polar solvents such as
dimethyldecylphosphoxide, methyloctylsulfoxide,
dimethyllaurylamide, dodecylpyrrolidone, isosorbitol,
dimethylacetonide, dimethylsulfoxide,
decylmethylsulfoxide, and dimethylformamide which
affect keratin permeability; salicylic acid which
softens the keratin; amino acids which are penetration
assistants; benzyl nicotinate which is a hair follicle
opener; and higher molecular weight aliphatic
surfactants such as lauryl sulfate salts which change
the surface state of the skin and drugs administered.
other agents include oleic and linoleic acids,
ascorbic acid, panthenol, butylated hydroxytoluene,
tocopherol, tocopheryl acetate, tocopheryl linoleate,
propyl oleate, and isopropyl palmitate.
In certain embodiments of the invention a
plasticizer or tackifying agent is incorporated into
the formulation to improve the adhesive
characteristics of the dermal composition. A
tackifying agent is particularly useful in those
embodiments in which the drug does not plasticize the
polymer. Suitable tackifying agents are those known
in the art including: (1) aliphatic hydrocarbons; (2)
mixed aliphatic and aromatic hydrocarbons; (3)
aromatic hydrocarbons; (4) substituted aromatic
hydrocarbons; (5) hydrogenated esters; (6)
polyterpenes; and (7) hydrogenated wood rosins. The
tackifying agent employed is‘ preferably compatible
with the blend of polymers. In preferred embodiments,
the ‘tackifying agent is silicone fluid (e.g., 360
Medical Fluid, available from Dow Corning Corporation,
Midland, MI) or mineral oil. Silicone fluid is useful
for blends comprising polysiloxane as a major
component. In other embodiments, where polyacrylate,
for example, is a major component, mineral oil is a
preferred tackifying agent.
Some drugs, such as the vasodilator
nitroglycerin, function as plasticizers in the
composition because they are soluble to a certain
degree in the polymers comprising the system. For
drug molecules which are not readily soluble in the
polymer system, a co-solvent for the drug and polymer
can be added. Co-solvents, such as lecithin, retinol
derivatives, tocopherol, dipropylene glycol,
triacetin, propylene glycol, saturated and unsaturated
fatty acids, mineral oil, silicone fluid, alcohols,
butyl benzyl phthalate, and the like are useful in the
practice of the instant invention depending on the
solubility of the drug in the multiple polymer
adhesive system.
To summarize, the preferred and optimum
compositions for the polyacrylate/polysiloxane
embodiment are as follows:
TABLE II
PERCENI BY WEIGHT
Preferred Optimum
Component Range Range
Polysiloxane 97-4 97-14
Polyacrylate 2-95 2-85
Co-solvent(s) 0-30 0-20
Enhancer(s) 0-20 0-10
Drug(s) 0.3-50 1-30
The composition of this invention may further be
provided with various thickeners, fillers and other
additives known for use with dermal compositions.
Where the composition tends to absorb water, for
example, when lecithin is used as a co-solvent,
hydrophilic fillers are especially useful. One type
of hydrophilic filler which has been successfully
employed is an aluminum silicate clay.
In a device aspect of the invention, the dermal
composition can be used as an adhesive portion of any
transdermal drug delivery device (e.g., a reservoir
device) or it can comprise an adhesive
monolithic device. of course, the principles of the
invention would still apply to embodiments where the
dermal composition is not a pressure—sensitive
adhesive and comprises the drug reservoir.
Reference to shows a schematic
illustration of an adhesive monolithic device
embodiment of the invention Lg. The dermal
composition comprises a monolithic body 11 of a
defined geometric shape with a protective release
liner 12 on one side of monolithic body 11 and a
backing layer 13 on the other side. Removal of the
release liner 12 exposes the pressure-sensitive
multiple polymer adhesive which functions both as the
drug carrier matrix and as the means of applying the
system to the patient.
A device, or individual dosage unit, of the
present invention can be produced in any manner known
to those of skill in the art" After the dermal
composition is formed, it may be brought into contact
with the backing layer in any manner known to those of
skill in the art. Such techniques include calender
coating, hot melt coating, solution coating, etc. of
course, backing materials are well known in the art
and can comprise plastic films of polyethylene, vinyl
acetate resins, ethylene/vinyl acetate copolymers,
polyvinyl chloride, polyurethane, and the like, metal
foils, non-woven fabric, cloth and commercially
available laminates. The backing material generally
has a thickness in the range of 2 to 1000 micrometers
and the dermal composition is generally disposed on
backing material in a thickness ranging from about 12
to 250 micrometers thick.
Suitable release liners are also well known in
the art and include the commercially available
products of Dow Corning Corporation designated Bio-
Releasec liner and Syl-off0 7610 liner. For preferred
embodiments in which a polysiloxane is part of the
multiple polymeric adhesive system, the release liner
must be compatible with the silicone adhesive. An
example of a suitable commercially available liner is
3M's 1022 Scotch Pak.
The configuration of the transdermal delivery
system of the present invention can be in any shape or
size as is necessary or desirable. Illustratively, a
single dosage unit may have a surface area in the
range of 1 to 200 cmK Preferred sizes are from 5 to
60 cmfl
In a method aspect of the invention, a plurality
of polymers having differing solubility parameters are
blended (but not chemically reacted or cross—1inked)
to result in a dermal composition, or multiple polymer
adhesive system with incorporated drug or bioactive
agent, which controls delivery of an incorporated drug
into and through. the epidermis. The blending of
polymers results in an adjustment of the saturation
concentration of the drug in the polymeric system and
therefore permits selective modulation of the
transdermal drug delivery rate. The term "blending,"
of course, incorporates choosing the appropriate
polymeric components, and the proportions thereof, to
achieve the desired effect.
IH1 a preferred embodiment of the invention, a
dermal composition is prepared by mixing the
polyacrylate, the polysiloxane, drug, co—solvent(s),
and tackifying agent, if needed, in an appropriate
volatile solvent(s), then. casting the mixture and
removing the solvent(s) by evaporation to form a film.
Suitable volatile solvents include, but are not
limited to, alcohols such as isopropanol and ethanol;
aromatics such as xylenes and toluene; aliphatics such
as hexane, cyclohexane, and heptane; and alkanoic acid
esters such as ethyl acetate and butyl acetate.
An exemplary general method of preparation is as
follows:
1. Appropriate amounts of polysiloxane and
polyacrylate, dissolved in a solvent(s), are combined
and thoroughly mixed together in a vessel.
2. The drug is then added to the polymer
mixture and agitation is carried out until the drug is
uniformly mixed in.
3. Co—solvents and enhancers, if necessary, can
then be added to the drug-polymer mixture, and
thoroughly mixed.
4. The fcnflation is then transferred to a
coating operation where it is coated onto a protective
release liner at a controlled specified thickness.
. The coated product is then passed through an
oven in order to drive off all volatile processing
solvents.
6. The dried product on the release liner is
then joined to the backing material and wound into
rolls for storage.
7. Appropriate size and shape dosage units are
die-cut from the roll material and then pouched.
The order of steps, the amounts of ingredients,
and the amount and time of agitation or mixing are
process variables which will depend on the specific
polymers, drug, co-solvents, and enhancers used in.the
formulation. These factors can be adjusted by those
of skill in the art as required to provide a uniform
product which has acceptable pressure—sensitive
adhesive characteristics.
Examples
The following specific examples are included as
illustrative of dermal compositions, and methods of
making same, within the contemplation of the
invention. These examples are in no way intended to
be limiting of the scope of the invention.
The following commercially available adhesives
were used in the blends comprising the multiple
polymer adhesive system of the examples: "Duro-Tak
80-1194, 80-1196, and 80-1197" are trademarks of
National Starch and Chemical Corporation, Bridgewater,
New Jersey for acrylic adhesives (polyacrylates) in
organic solutions.
"BIO-PSA X7-3027, X7-4919, X7-2685, and X7—3l22"
are trademarks of Dow Corning Corporation, Medical
Products, Midland, Michigan for silicone adhesives
(polysiloxanes) in organic solutions. BIO-PSA-3027 is
particularly suitable for use in. formulations
containing amine-functional drugs, such as albuterol
and pilocarpine, in the following examples.
"Vistanex LM-LS-LC" is a trademark of Exxon
Chemical Company, Houston, Texas, for a
polyisobutylene polymer with a Flory molecular weight
of 42,600 to 46,100.
"Elvax 40-W" is a trademark of Du Pont Company,
Wilmington, Delaware, for a polyethylene/vinyl acetate
copolymer (40% vinyl acetate content).
The aforementioned polymeric adhesives are
supplied, or prepared, as solutions wherein the
percent solids by weight are as follows:
Ingredient Percent Solids
BIO-PSA X7-3027 50
BIO-PSA X7-3122 65
BIO-PSA X7-4919 50
BIO-PSA X7-2685 50
Duro-Tak 80-1194 45
Duro-Tak 80-1196 45
Duro-Tak 80-1197 45
Elvax 40-W 30
Vistanex LM-MS-LC 30
"360 Medical Fluid" is a trademark of Dow Corning
Corporation for a polydimethylsiloxane fluid. In
certain embodiments of the invention, 360 Medical
Fluid is added as a tackifier to improve the adhesive
characteristics of the end product.
E§Afi2L§_1
A nitroglycerin—polymer mixture was prepared by
combining 22.0 parts of nitroglycerin, 1.0 part of
dipropylene glycol, 1.3 parts of lecithin, 0.8 parts
of propylene glycol, 2.5 parts of 360 Medial Fluid
(1000 cs), 1.0 part of bentonite, 63.6 parts of
polyacrylate (Duro—Tak 80-1194), and 85.6 parts of
polysiloxane (BIO-PSA X7—4919), and mixed well in an
appropriate container. Hitroglycerin is available as
a solution in solvents such as ethanol, toluene, and
propylene glycol from ICI Americas Inc., Wilmington,
Delaware. In this instance, the nitroglycerin was
added as a solution in toluene mixed together with the
polyacrylate. The resulting composition had the
ingredient concentrations on a "dry" basis, that is,
after removal of volatile process solvents, shown
below.
OMPONE EERCENT B! EEIQI-LT
Polysiloxane 42.8
(Dow Corning Silicone Adhesive X7-4919)
Polyacrylate 28.6
(National Starch Acrylic Adhesive,
Duro—Tak 80-1194)
Polydimethylsiloxane fluid 2.5
(Dow Corning 360 Medical Fluid)
Lecithin 1.3
Propylene glycol 0.3
Dipropylene glycol 1.0
Bentonite 1.0
Nitroglycerin 22.0
100.0
Nitroglycerin flux results through cadaver skin
in vitro from the formulation of Example 1,
Transderm-Nitro® (a trademark of Ciba-Geigy
Corporation, Summit, NJ), and Nitro-Dur® (a trademark
of Key Pharmaceuticals, Inc., Kenilworth, NJ) are
summarized in As shown in
nitroglycerin flux from the dermal composition of
Example 1 (20.8 ug/cmdufi was approximately twice that
from Iransderm-Nitro® (9.5 pg/cmdufi and about 1.5
times that from Nitro—Dur® (13.4 pg/cmfinfl.
E LE -
In the following examples (2-5), the method of
Example 1 was used with the appropriate amounts of
starting materials to yield compositions having the
following ingredient concentrations set forth in
tabular form in TABLE III. Example 2 is presented for
comparative purposes and its formulation is not within
the scope of the present invention. Example 3 and S
are adhesive compositions comprising blends of
polyacrylate and a second polymer selected to
illustrate the principles of the invention. All other
components, such as excipients or fillers, remain
constant in composition and amount from Examples 2 to
IABLE III
Examples (96, w/w)
Ingredient (SP, J "2/cm“) 2 3 4 5
Polyacrylate (21) 73.2 33.1 33.1 33.1
Polyethylene vinyl acetate (21) - 40.1 -— --
Polyisobutylene (17) - -- 40.1 --
Pcdysfloxane (15) —— -- -- 40.1
Nitroglycerin (27) 20.8 20.8 20.8 20.8
Oleic acid 2.0 2.0 2.0 2.0
Propylene glycol 0.8 0.8 0.8 0.8
Ixxfimn L2 L2 12 L2
Dipropylene glycol 1.0 1.0 1.0 1.0
mmmmm L0 L0 10 10
graphically summarizes the in vitro
nitroglycerin flux results through cadaver epidermis
from the dermal compositions of Examples 2 to 5. As
seen in addition of either polyisobutylene
(Example 4) or polysiloxane (Example 5) -- both with
SPs lower than polyacrylate -- resulted in doubling of
the nitroglycerin flux as compared to an all acrylate
system (Example 2). However, addition of polyethylene
vinyl acetate (Example 3) —- with an SP value similar
to the polyacrylate -- resulted in little effect on
nitroglycerin flux as compared to the system of
Example 2. Thus, the formulation of Example 3 is not
within the scope of the present invention.
EXAMPLE 6
A series of nitroglycerin-containing compositions
(I-VI) were prepared in which the polyacrylate (X7-
3122) to polysiloxane (Duro-Tak 80-1194) ratio was
varied from 100.0 : 0.0 (all acrylic) to 0.0 : 100.0
(all siloxane) by weight. Nitroglycerin concentration
was held at 20% for all compositions. The ingredient
concentrations of these compositions are shown below
in TABLE IV.
ABLE I
I U. J11 1‘:’_ V VI
Polysiloxane -- 14.4 28.8 43.2 57.6 72.6
SiliconeF1uid -- 1.6 3.2 4.8 6.4 8.0
Polyacrylate 80.0 64.0 48.0 32.8 16.0 --
Nitroglycerin 20.0 20.0 20.0 20.0 20.0 20.0
In vitro skin flux was determined for
these compositions and the results are summarized in
Table V and graphically depicted in
TABLE v
% of Polymer (pg/cm 2/hr) (hr)
CQr1\12c2§i1i_<>n_.!’_c~_ly.a9;r,v_l_;xls; Polvs.i.l.01
I 100 0 1.6 0.0
II 81.6 13.4 3.2 1.5
III 62.5 37.5 4.2 2.0
IV 43.2 56.8 4.5 2.3
V 21.7 78.3 5.2 2.3
VI 0 100 4.9 2.4
Nitro—Dur° — -- 3.0 2.5
As shown, nitroglycerin (GTN) flux increased as
the concentration of polysiloxane in the multiple
polymer adhesive matrix increased up to a maximum, at
around 80% polysiloxane, after which no more increase
‘in flux was seen. It appears that beyond a certain
concentration of siloxane polymer, the nitroglycerin
activity ceases to increase (unit activity is
reached), and the flux no longer increases. The
attainment of saturation concentration (unit activity)
is further verified by the fact that Composition VI
had nitroglycerin exudate; that is, the surface of the
adhesive was "wet" with excess nitroglycerin. of
course, Composition VI, which is all polysiloxane, is
not within the contemplation of the invention.
The composition of the blend of polymers is
preferably chosen so that the flux rate of drug from
the blend is at a maximum. Studies similar to those
reported herein may be employed to assist in selecting
the appropriate components of the blend and the weight
ratios thereof. In alternative embodiments, it may be
desirable to select a composition in which the flux
rate will be retarded.
XAHPL -
An estradiol-polymer mixture (Example 7) was
prepared by combining 2.0 parts of 17B—estradio1, 2.0
parts of propylene glycol, 3.0 parts of lecithin, 5.0
parts of oleic acid, 5.0 parts of dipropylene glycol,
93.3 parts of polyacrylate (Duro-Tak 80-1196), and
63.1 parts of polysiloxane (BIO-PSA. X7-3122), and
mixing well in an appropriate container. The
resulting composition had the ingredient concentra-
tions on a "dry" basis, that is, after removal of
volatile process solvents, given below in TABLE VI.
Examples 8 and 9 were made in accordance with.the
method of Example 7. The compositions of Examples 8
and 9 have the same drug and additional components,
such as the co-solvents, as Example 7, but are not
within the scope of this invention inasmuch as the
resulting adhesive matrices are single polymer
systems. Examples 8 and 9 are given for comparative
purposes only.
TABLE 21
Examples (96, w/w)
lngr-;
Polyacrylate 42.0 83.0 --
Polysiloxane 41.0 -- 83.0
Estradiol 2.0 2.0 2.0
Oleic acid 5.0 5.0 5.0
Propylene glycol 2.0 2.0 2.0
Lecithin 3.0 3.0 3.0
Dipropylene glycol 5.0 5.0 5.0
Estradiol flux in vitro from the systems of
Examples 7, 8, and 9 is shown in As seen in
delivery from the system of this invention
utilizing the multiple polymer adhesive
(polyacrylate/polysiloxane) of Example 7 was
substantially greater than delivery from the prior art
systems comprising single polymer adhesives (Examples
8 and 9).
EQPLEB 10 - 13
In the following examples (10-13), the method of
Example 7 was used with the appropriate amounts of
starting materials to yield compositions having the
ingredient concentrations set forth in TABLE VII.
gangs VII
Examples (15, w/w) Q
17 lg’
iI1;;rl_'I_HI,'_!1l ll) I
Polysiloxane 18.0 33.5 39.5 53.0
Polyacrylate 65.0 39.5 33.5 15.0
Estiadiol 2.0 2.0 2.0 2.0
Oleic acid 5.0 5.0 5.0 5.0
Propylene glycol 2.0 2.0 2.0 2.0
Lecithin 3.0 3.0 3.0 3.0
Silicone fluid 5.0 15.0 15.0 15.0
shows estradiol flux results for the
compositions of Examples 10 - 13; average flux was
calculated for each composition from 0 to 22 hours and
from 22 to 99 hours from the start of the study. As
seen in estradiol flux progressively increased
with increased silicone polymer content during the
first 22 hours of delivery, but was affected to a much
lesser degree during the remainder of the study (22 to
99 hours). Thus, significant adjustment of the
estradiol delivery rate during the initial phase of
delivery was accomplished, with minor effects on the
later delivery phase, by modulating the polysiloxane
to polyacrylate polymer ratio. Fig 6 also illustrates
that the delivery characteristics over time can be
adjusted by the appropriate choice of polymers and
respective weight ratios. For example, the
formulation of Example 10 delivers drug at
approximately the same rate over time whereas the
formulation of Example 13 delivers more quickly in the
early phase than the latter.
§XAMP§§§ Lg - lfi
A norethindrone acetate-polymer mixture was
prepared by combining 0.6 parts of norethindrone
acetate, 1.0 parts of butylene glycol, and 40.9 parts
of polyacrylate (Duro-Tak 80-1194), and mixing well in
an appropriate container. The resulting composition
had the ingredient concentrations on a "dry" basis,
that is, after removal of volatile process solvents,
given below in TmBLE VIII. The same method was
employed to make Examples 15 and 16.
TABLE VIII
Examples (% wlw)
Ingredient 14 15 16
Polyacrylate 92.0 —- 46.0
Polysiloxan - 92.0 46.0
Nomflmmmmemxmm 30 10 30
Butylenc glycol 5.0 5 .0 5.0
Norethindrone acetate flux in vitro from the
systems of Examples 14, 15, and 16 is shown in
As seen in norethindrone acetate delivery from
the polyacrylate/polysiloxane systems of this
invention (Example 16) was intermediate to delivery
from the single polymer systems not of this invention
(Example 14 and 15). Thus, blending the polyacrylate
and polysiloxane results in modulation of the
norethindrone acetate flux.
E§A§ELE8 ;7 - 29
As estradiol/norethindrone acetate combination-
polymer mixture was prepared by combining 0.6 parts of
176 estradiol, 0.6 parts of norethindrone acetate, 0.6
parts of butylene glycol, 0.6 parts of oleic acid, 1.5
parts of lecithin, 4.5 parts of silicone fluid
(polydimethylsiloxane fluid, Dow Corning 360 Medical
Fluid, 100 cs), and 43.2 parts of polysiloxane (BIO-
PSA x7—4919), and mixing well in an appropriate
container. The method of Example 17 was used with the
appropriate amounts of starting materials to yield the
compositions of Example 18, 19 and 20. The
polyacrylate used in Examples 18~20 was National
Starch Acrylic Adhesive, Duro~Tak 80-1197. The
resulting compositions had the ingredient
concentrations on a "dry" basis, that is, after
removal of volatile process solvents, given below in
TABLE IX.
EABLE IX
Examples (% w/w)
Ingredient 17 18 19 ZCL
Polysiloxan 72.0 68.0 60.0 47.0
Polyacrylate — 5.0 15.0 30.0
Ebumfiol Z0 10 10 20
Norethindrone acetate 2.0 2.0 2.0 2.0
Oleic acid 2.0 2.0 2.0 2.0
Butylene glycol 2.0 2.0 2.0 2.0
Iedflfin i0 10 50 50
Silicone fluid 15.0 14.0 12.0 10.0
Flux results for the compositions of Examples 17-
are shown in Fig. 8. As shown in Fig. 8, the flux
of both estradiol (E2) and norethindrone acetate (NAC)
varied as the polysiloxane to polyacrylate polymer
ratio was adjusted; estradiol flux gradually increased
and then decreased with a maximum at about 15%
acrylate, and the norethindrone acetate flux
continuously decreased with increasing acrylate
content as would be expected from the data of Fig. 7.
A further effect of varying the poly-
siloxane/polyacrylate polymer ratio is exhibited by a
plot of estradiol flux relative to norethindrone
acetate flux (estradiol flux divided by norethindrone
acetate flux) as shown in Fig. 9. By adjusting the
silicone to acrylate polymer ratio, it was possible to
modulate the relative delivery of two drugs (estradiol
and norethindrone acetate) from the systems of this
invention .
EfiL§gL§8 2; - Z}
A pilocarpine-polymer mixture was prepared by
combining 5.0 parts of pilocarpine base, 1.2 parts of
lecithin, 0.8 parts of propylene glycol, 2.0 parts of
oleic acid, 2.5 parts of silicone fluid
(polydimethylsiloxane, Dow Corning 360 Medical Fluid,
100 cs), and 77.0 parts of polysiloxane ( Dow Corning
Silicone Adhesive BIO—PSA X7-3027), and mixing well in
an appropriate container. Example 22 incorporated
pilocarpine into a polyacrylate comprising National
Starch Acrylic Adhesive, Duro-Tak 80-1196. Example 23
employed a blend of polysiloxane and polyacrylate in
accordance with the principles of the invention. The
resulting compositions had the ingredient
concentrations on a "dry" basis, that is, after
removal of volatile process solvents, given below in
TABLE X.
_BEL__X
l xx1n;fl:t» I96 xv/xv)
lngnghvué ?l 3? 3}
Polyactylate - 82.0 41 .0
Polysiloxane 77.0 —- 41 .0
Silicone Fluid 5.0 - --
Pilocarpine 10.0 10.0 10.0
Oleic acid 4.0 4.0 4.0
Propylene glycol 1.6 1.6 1.6
Ledflfin 24 2A 14
Pilocarpine flux in vitro from the systems of
Examples 21, 22, and 23 is shown in Fig. 10. As seen
in Fig. 10, the delivery rate from the system of this
invention utilizing the multiple polymer adhesive
(polyacrylate/polysiloxane) of Example 23, was
intermediate of the delivery rates from single polymer
compositions (Examples 21 and 22) which are not of
this invention. In this embodiment of the invention,
the combination of polyacrylate and polysiloxane
polymers adjusted the delivery of rate of pilocarpine
within the ranges established by single polymer
compositions.
ޤ;ggLEB 34 - 32
An albuterol-polymer mixture was prepared by
combining 10.2 parts of albuterol base, 1.5 parts of
lecithin, 1.0 part of propylene glycol, 4.1 parts of
oleic acid, 2.6 parts of dipropylene glycol, 1.5 parts
of butylene glycol, 1.5 parts of vitamin E acetate
(tocoperyl acetate), 25.5 parts of polyacrylate (Dure-
Tak 80-1196), 11.9 parts of polysiloxane A (BIO-PSA
X7-3122), 20.1 parts of polysiloxane B (BIO-PSA X7-
3027), and 20.1 parts of isopropyl alcohol, and mixing
well in an appropriate container. The resulting
composition had the ingredient concentrations on a
"dry" basis, that is, after removal of volatile
process solvents, given below in Table XI.
The. method of Example 24 was used with the
appropriate amounts of starting materials to yield the
compositions of Examples 25, 26, and 27.
EALILKI
Examples (96 ‘-V/\.\|
lLgnflnnI J4 If 20
Polysiloxane A 14.0 13.8 14.0 14.0
Polysiloxane B 19.6 19.2 28.0 19.6
Polyacrylate 22.4 22.0 20.0 22.4
Albuterol 20.0 20.0 20.0 20.0
Oleic acid 8.0 8.0 8.0 8.0
Propylene glycol 2.0 2.0 2.0 2.0
Dipropylene glycol 5.0 5.0 5.0 5.0
Butylcne glycol 3.0 3.0 - 3.0
Vitamin E acetate 3.0 3.0 -- -
Vitamin E - 1.0 -- --
Vitamin E linoleatc — — -— 3.0
Lecithin 3.0 3.0 3.0 3.0
Albuterol flux results through human cadaver skin
in vitro from the formulations of Examples 24, 25, 26,
and 27, are summarized in Fig. 11,- nitroglycerin flux
from Nitro-Dur® through the same skin specimen is
shown as a control. Flux values for the albuterol
compositions of Example 24 to 27 ranged from about 17
pg/cm’/hr to about 22 pg/cm’/hr. The nitroglycerin
flux value of about 28 ug/cm’/hr was slightly higher
than the literature delivery rate for this product (20
pg/cm’/hr, based on Nitro—Dur® product label of 0.1
mg/hr from a 5 cm2 system). In order to adjust for the
apparent higher permeability of the skin specimen,
albuterol flux results can be multiplied by an
adjustment factor of 0.714 (20/28); this would result
in flux values of about 12 pg/cm”/hr to about 16
pg/cm’/hr.
Therapeutic albuterol plasma concentrations are
in the range of about 4 to 8 ng/mL, and are produced
by delivery rates of about 115 to 230 pg/hr. The flux
rates (12 to 16 #9/Cm’/hr) obtained from the
compositions of this invention therefore would produce
the necessary albuterol plasma levels (4 to 8 ng/mL)
for the treatment of asthma from system sizes of about
to 20 cm’.
EXAMPLES 28 - 29
Estradiol-polymer mixtures were prepared in
accordance with the method of Example '7. Example 28
is illustrative of a multiple polymer adhesive system
where polyacrylate is blended with polyisobutylene
(vistanex LM-LS-LC) . The resulting compositions had
the ingredient concentrations on a "dry" basis, that
is, after removal of volatile process solvents, given
below in TABLE XII.
TABLE XII
Examples (96, w/w)
I_uur:2<_Jicm .78 _ 29 ..
Polyacrylate 45.0 45 .0
Polyisobutylene 45.0 -
Polysiloxane —- 45.0
Estradiol 2.0 2.0
Oleic acid 5.0 5 .0
Lecithin 3.0 3.0
Estradiol flux in vitro from the systems of
Examples 28 and 29 are shown in . As seen in
, delivery from the multiple polymer adhesive
system of Example 28 is comparable to delivery from
Example 2 9 .
In addition to flux measurements, the apparent
diffusion coefficient, D, was calculated from release
data for nitroglycerin from matrices of Compositions
I to VI (Example 6) into an infinite sink. The method
of D.R. Paul, mm-2 01 l__r>;.i _§{§‘l§.f_g-’.it"-l‘_ W» I j_.'n\c-1‘i{_j
Formulations. ACS Symposium Series No. 33, Chapter 1
(1976) was used wherein the initial concentration of
nitroglycerin in the matrix, Co, was determined
(assuming a density of 1.0) and the relationship of
the amount released, M" by a matrix of area, A, and
the diffusion coefficient is defined by:
“JR = 20o (Dt/Tr)“
Plotting, M,/A against tm, results in a graph
having a slope, 111, defined by:
m = 2c,, (D/1:)“
The value of m can be ascertained by linear
regression to get the slope of the best fit line. The
diffusion coefficient is calculated as:
D = 1r(m/2C0)’
The results of these calculations for
Compositions I to VI are shown below in Table XII.
ELQLE XIII
Compositio@(mg/cmfim (mg/cm%f”D nnfi/sec) D(x10H
I 241.0 u.8?28 2.5n1 x 10” ‘€$M
II 233.3 0.9483 ’.n9u x 10* u;.oe
111 231.3 1_na3a 4.780 x 10‘ ‘Y/AH}
IV 219.7 1.230! ?.unw M 1L:‘ 7fl.n5
V 217.0 3.&u20 1.174 x 19' 217.4
VI 215.0 :.;:&1 3.34. . 10“ ¢s4.m
Nitro-Dun80.0 1.45am 7.2un x lo‘ .HL\m
FIGS. 13 and 14 show the relationship of flux rate
(J) plotted against apparent diffusion coefficient (D)
and net solubility parameter (SP), respectively, for
Compositions I-VI. The net solubility parameter, SP“
was calculated using a weighted average of the
solubility parameters of the individual polymers
comprising the matrix:
SP,“ = ewspp, + ¢,_sP_,
where 6" is the weight percentage of polysiloxane and
SP, is the solubility parameter of polysiloxane. The
subscript "pa" refers to the polyacrylate. is
a plot of diffusion coefficient versus net solubility
parameter.
Although the invention has been described in terms
of specific embodiments and applications, persons
skilled in the art can, in light of this teaching,
generate additional embodiments without exceeding the
scope or departing from the spirit of the claimed
invention. Accordingly, it is to be understood that
the drawing and description in this disclosure are
proffered to facilitate comprehension of the
invention, and should not be construed to limit the
scope thereof.
Claims (112)
- CLAIMS pressure-sensitive adhesive An improved composition of the type suitable for controlled release of a bioactive agent from a pressure—sensitive adhesive matrix, the composition comprising: first a blend of a first polymeric adhesive having a first solubility parameter and a second polymeric adhesive having a second solubility parameter, the first and second solubility parameters being different from one another by an increment of at least 2 (J/cm’)“7 and resulting in a characteristic net solubility parameter of the blend which can selectably adjust the saturation concentration of a bioactive agent contained in the pressure- sensitive adhesive composition and thereby modulate the release of the bioactive agent.
- A transdermal drug delivery system comprising (1) a blend of: (a) a first polymeric material having a solubility parameter, and (b) a second polymeric material having a second solubility parameter, said first and second solubility parameters being different from one another and resulting in a preselected net solubility parameter of the blend; and (2) a drug, wherein the net solubility parameter of the blend is preselected to determine the solubility of the drug in the blend.
- The transdermal drug delivery system of claim 2 wherein the blend is a pressure-sensitive adhesive.
- The tr: lzsdermal drug delivery system of claim 3 further com; _sing a backing material superimposed on one surface of the pressure sensitive adhesive, said backing material being substantially impermeable to the drug contained therein.
- 5. The transdermal drug delivery system of claim 3 further comprising a release liner superimposed on a surface of the pressure sensitive adhesive opposite said backing material.
- 6. The transdermal drug delivery system of any one of claims 2 to 5. wherein the drug is a steroid.
- 7. The transdermal drug delivery system of claim 6 wherein the steroid is an estrogen selected from the group consisting of conjugated estrogens, esterified estrogens, estropipate, 17B—estradiol, equilin, mestranol, estrone, estriol, ethinyl estradiol, and diethylstilbestrol.
- 8. The transdermal drug delivery system of claim 6 wherein the steroid is a progestational agent.
- 9. The transdermal drug delivery system of claim 8 wherein the progestational agent is selected from the group consisting of progesterone, 19-norpro- gesterone, norethindrone, norethindrone acetate, melengestrol, chlormadinone, ethisterone, medroxy~ progesterone acetate, hydroxyprogesterone caproate, ethynodiol diacetate, norethynodrel, 17a-hydroxy- progesterone, dydrogesterone, dimethisterone, ethinylestrenol, norgestrel, demegestone, promegestone, and megestrol acetate.
- 10. The transdermal drug delivery system of * M anywgne of claimsiz to_§. wherein the drug is a 3,-adrenergic agonist.
- 11. The transdermal drug delivery system of claim 10 wherein the firadrenergic agonist is selected from the group consisting of metaproterenol, terbutaline, albuterol, carbuterol, rimiterol, salmefamol, fenoterol, soterenol, tratoquinol, and quinterenol.
- 12. The transdermal drug delivery system of _ any one of claims 2 to 5. wherein the drug is a cardioactive agent.
- 13. The transdermal drug delivery system ofnslaim 12 wherein said cardioactive agent is selected from the group consisting of nitroglycerin, isosorbide dinitrate, isosorbide mononitrates, quinidine sulfate, procainamide, benzydroflumethiazide, bendroflumethiazide, chlorothiazide, nifedipine, nicardipine, verapamil, diltiazem, timolol, propranolol, captopril, clonidine and prazosin.
- 14. The transdermal drug delivery system of any one of claims 2 to 5. wherein the drug is a cholinergic agonist.
- 15. The transdermal drug delivery system of claim 14 wherein the cholinergic agonist is selected from the group consisting of choline, acetylcholine, methacholine, carbachol, bethanechol, pilocarpine, muscarine, and arecoline.
- 16. The transdermal drug delivery system of , w~s . any one of claims 2 to 15. wherein the drug is intimately mixed with the blend.
- 17. The transdermal drug delivery system of any__ one of claims 2 to 16. wherein said system is a reservoir device having an adhesive portion comprised of said blend.
- 18. The transdermal drug delivery system of " " “* anY_One_ot_clg1ms 2 to 17. wherein said first polymeric material is a polyacrylate.
- 19. The transdermal drug delivery system of claim 18 wherein the second polymeric material is a polysiloxane.
- 20. The transdermal drug delivery system of claim 19 wherein the polyacrylate is present in an amount ranging from about 2% to about 96% by weight of the blend and the polysiloxane is present in an amount ranging from about 98% to about 4% by weight of the blend.
- 21. The transdermal drug delivery system of claim 7 wherein the estrogen is 17fl-estradiol and the 17B- estradiol is present in the system in an amount of from about 1% to about 5% by weight.
- 22. The transdermal drug delivery system of claim 9 wherein the progestational agent is norethindrone acetate and the norethindrone acetate is present in the system in an amount of from about 1% to about 5% by weight.
- 23. The transdermal drug delivery system of claim 11 wherein the 5,-adrenergic agonist is albuterol and the albuterol is present in the system in an amount of less than about 30% by weight.
- 24. The transdermal drug delivery system of claim 13 wherein the cardioactive agent is nitroglycerin and the nitroglycerin is present in the system in an amount of less than about 25% by weight.
- 25. The transdermal drug delivery system of claim 15 wherein the cholinergic agonist is pilocarpine and the pilocarpine is present in the drug-containing polymeric diffusion matrix in an amount of less than about 30% by weight.
- 26. The transdermal drug delivery system of any one of claims 2 to 5. wherein the drug is a tranguilizer.
- 27. The transdermal drug delivery system of claim 26 wherein the tranquilizer is selected from the group consisting of alprazolam, chlordiazepoxide, clorazeptate, halazepam, oxazepam, prazepan, clonazepam, flurazepam, triazolam, lorazepam and diazepam.
- 28. The transdermal drug delivery system of claim 27 wherein the tranquilizer is alprazolam.
- 29. The transdermal drug delivery system of anvone of gclaims 2 to 5. wherein the drug is an antipsychotic.
- 30. The transdermal drug delivery system of claim 29 wherein the antipsychotic is selected from the group consisting of thiopropazate, chlorpromazine, triflupromazine, mesoridazine, piperacetazine, thioriclazine, acetophenazine, fluphenazine, perphenaz- ine, trifluoperazine, chlorprathixene, thiothixene, haloperidol, bromperidol, loxapine and molindone.
- 31. The transdermal drug delivery system of claim 30 wherein the antipsychotic is haloperidol.
- 32. The transdermal drug delivery system of any one __o_fW<;1ai_111s 2, to 5. wherein the drug is an anesthetic.
- 33 . The transdermal drug delivery system of claim 32 wherein the anesthetic is selected from the group consisting of lidocaine, tetracaine, dyclonine, d ibucaine , cocaine , procaine , mepivacaine , bupivacaine, etidocaine, prilocaine and benzocaine.
- 34. The transdermal drug delivery system of claim 33 wherein the anesthetic is lidocaine.
- 35. The transdermal drug delivery system of 1 am .Qm:_oL_q1.a_1.i1I;s__2.it9. 5.,-. wherein the drug is an analgesic.
- 36. The transdermal drug delivery system of claim 35 wherein the analgesic is selected from the group consisting of fentanyl, buprenorphine and codeine.
- 37. The transdermal drug delivery system of .'....Lv« ‘N ranywopg o£_,_c1 §‘_ wherein the drug has an action on the central nervous system.
- 38. The transdermal drug delivery system of claim 37 wherein the drug is nicotine.
- 39. The transdermal drug delivery system of any one of claims 2 togj. comprising a mixture of at least two drugs.
- 40. The transdermal drug delivery system of claim 39 comprising a mixture of a progestational agent and an estrogen.
- 41. The transdermal drug delivery system of claim 40 wherein said progestational agent is selected from the group consisting of progesterone, 19-norpro- gesterone, norethindrone, norethindrone acetate, melengestrol, chlormadinone, ethisterone, medroxy- progesterone acetate, hydroxyprogesterone caproate, ethynodiol diacetate, norethynodrel, 1'7a-hydroxy- progesterone , dydrogesterone , dimethisterone , ethinylestrenol, norgestrel, demegestone, promegestone, and megestrol acetate.
- 42. The transdermal drug delevery system of claim 41 wherein said progestational agent is norethindrone acetate.
- 43. The transdermal drug delivery system of claim 40 wherein said estrogen is selected from the group consisting of conjugated estrogens, esterified estrogens, estropipate, 176—estradio1, equilin, mestranol, estrone, estriol, ethinyl estradiol, and diethylstilbestrol.
- 44. The transdermal drug delivery system of claim 43 wherein said estrogen is 17B-estradiol.
- 45. The transdermal drug delivery system of _an){__c>_l_1_§ of claims 2 to,§,§__., wherein the first and second solubility parameters are different from one another by an increment of at least about 2 (J/cm3)lI2.
- 46. The transdermal drug delivery system of claim 45 wherein the first and second solubility parameters are different from one another by an increment of at least about 4 (J/cmfi'”.
- 47. The transdermal drug delivery system of ' 9‘ any one of claims 2>to 46. wherein said system achieves an increased permeation rate of the drug through the dermis of a subject relative to the permeation rate achieved by a system comprising said first polymeric material as the sole polymeric material.
- 48. The transdermal drug delivery system of any one of clagm;_2nto_4§; wherein said system achieves a decreased permeation rate of the drug through the dermis of a subject relative to the permeation rate achieved by a system comprising said first polymeric material as the sole polymeric material.
- 49. The transdermal drug delivery system of ' any one of claims 2 N§9__5§4 further comprising an additive selected from the group consisting of an enhancer, a filler, a co-solvent and an excipient. so, .
- A transdermal drug delivery system comprising: (a) a multiple polymer adhesive system consisting essentially of a blend of about 2% to about 96% by weight of an acrylic-based polymer and about 98% to about 4% by weight of a silicone-based polymer, the multiple polymer adhesive system being in an amount of about 99% to about 50% by weight of the system; (b) a drug in the amount of about 0.3% to about 50% by weight of the system; (c) an effective amount of a co-solvent for the drug, said amount being up to about 30% by weight of the system; and an effective amount of an enhancer, said amount being up to about 20% by weight of the system.
- 51. The transdermal drug delivery system of claim 50 further comprising fillers and excipients in an amount of about 1% to about 15% by weight of the dermal adhesive composition. .
- 52. ,— The transdermal drug delivery system of claim 2 comprising at least two drugs.
- 53. A method of making a transdermal drug delivery system of the type having a drug-containing pressure-sensitive adhesive, the method comprising the steps of: (1) producing a mixture of (a) a blend of a first polymeric material having a first solubility parameter, and a second polymeric material having a second solubility’ parameter, said first and second solubility parameters being different from one another and resulting in a preselected net solubility parameter of the blend, and (b) a drug; and (2) forming the mixture into a pressure- sensitive adhesive matrix.
- 54. The method of claim 53 further comprising the step of applying a backing material to one side of the pressure—sensitive adhesive matrix, said backing material being substantially impermeable to the drug contained therein.
- 55. The method of claim 54 further comprising the step of applying a release liner to a surface of the pressure-sensitive adhesive matrix opposite said backing material.
- 56. The method of any one of gl§ims_§3 to 55. wherein an additive selected from the group consisting of an enhancer, a filler, a co-solvent and an excipient is combined with said mixture prior to forming the mixture into the pressure-sensitive adhesive matrix.
- 57. The method of to 56. wherein the drug is intimately mixed with the any one of claims 53 blend.
- 58. The method of to 57. wherein said system. is a reservoir device having an adhesive portion comprised of said blend. agv one of claims R1 any one of claims 53
- 59. The method of to 53. wherein said first polymeric material is a polyacrylate.
- 60. The method of claim 59 wherein the second polymeric material is a polysiloxane.
- 61. The method of claim 60 wherein the ratio of polyacrylate to polysiloxane is from about 2:98 to about 96:4 by weight of the pressure-sensitive adhesive matrix.
- 62. The method of claim 61 wherein the ratio of polyacrylate to polysiloxane is from about 2:98 to about 90:10 by weight of the pressure-sensitive adhesive matrix.
- 63. The method of claim 62 wherein the ratio of polyacrylate to polysiloxane is from about 2:98 to about 86:14 by weight of the pressure-sensitive adhesive matrix.
- 64. The method of :' to 63. wherein the drug is present in an amount ranging from about 0.3% to about 50% by weight of the pressure-sensitive adhesive matrix.
- 65. The method of 1*”, 1; any one_ofH9Laim§_53 to 64. wherein the drug is a steroid. any one of claims 53
- 66. The method of claim 65 wherein the steroid is an estrogen selected from the group consisting of conjugated estrogens, esterified estrogens, estropipate, 17B-estradiol, equilin, mestranol, estrone, estriol, ethinyl estradiol, and diethylstilbestrol.
- 67. The method of claim 66 wherein the estrogen is 173-estradiol and the 17B-estradiol is present in the pressure-sensitive adhesive matrix in an amount of from about 1% to about 5% by weight.
- 68. The method of claim 65 wherein the steroid is a progestational agent.
- 69. The method of claim 68 wherein the progestational agent is selected from the group consisting of progesterone, 19-norprogesterone, norethindrone, norethindrone acetate, melengestrol, chlormadinone, ethisterone, medroxyprogesterone acetate, hydroxyprogesterone caproate, ethynodiol diacetate, norethynodrel, 17a-hydroxyprogesterone,, dydrogesterone, dimethisterone, ethinylestrenol, norgestrel, demegestone, promegestone, and megestrol acetate.
- 70. The method of claim 69 wherein the progestational agent is norethindrone acetate and the norethindrone acetate is present in the pressure- sensitive adhesive matrix in an amount of from about 1% to about 5% by weight.
- 71. The method of to 64._wherein the drug is a Bf-adrenergic agonist.
- 72. The method of claim 53 wherein the B2-adrenergic agonist is selected from the group consisting of metaproterenol, terbutaline, albuterol, carbuterol, rimiterol, salmefamol, fenoterol, soterenol, tratoquinol, and quinterenol. any one_of c1aims,53
- 73. The method of claim 72 wherein the B5- adrenergic agonist is albuterol and the albuterol is present in the pressure-sensitive adhesive matrix in an amount of less than about 30% by weight.
- 74. The method of any one of claims 53 to 64. wherein the drug is a cardioactive agent.
- 75. The method of claim 74 wherein said cardioactive agent is selected from the group consisting of nitroglycerin, isosorbide dinitrate, isosorbide mononitrates, quinidine sulfate, procainamide, benzydroflumethiazide, bendroflumethiazide, chlorothiazide, nifedipine, nicardipine, verapamil, diltiazem, timolol, propranolol, captopril, clonidine and prazosin.
- 76. The method of claim 75 wherein the cardioactive agent is nitroglycerin and the nitroglycerin is present in the pressure-sensitive adhesive matrix in an amount of less than about 25% by weight.
- 77. The method of “' to 64. wherein the drug is a cholinergic agonist.
- 78. The method of claim 77 wherein the cholinergic agonist is selected from the group consisting of choline, acetylcholine, methacholine, carbachol, bethanechol, pilocarpine, muscarine, and any one of claims 53 arecoline.
- 79. The method of claim 78 wherein the cholinergic agonist is pilocarpine and the pilocarpine is present in the pressure-sensitive adhesive matrix in an amount of less than about 30% by weight.
- 80. The method of claim 53 wherein the drug is a tranquilizer.
- 81. The method of claim 80 wherein the tranquilizer is selected from the group consisting of alprazolam,chlordiazepoxide,c1orazeptate,ha1azepam, oxazepam, prazepam, clonazepam, flurazepam, triazolam, lorazepam and diazepam.
- 82. The method. of claim 81 wherein the tranquilizer is alprazolam.
- 83. The method of to 64. wherein the drug is an antipsychotic. any one of claims 53
- 84. The method of claim 83 wherein the antipsychotic is selected from the group consisting of thiopropazate, chlorpromazine, triflupromazine, mesoridazine, piperacetazine, thioridazine, acetophenazine, fluphenazine, perphenazine, trifluoperazine, chlorprathixene, thiothixene, haloperidol, bromperidol, loxapine and molindone. B5.
- The method. of claim 84 wherein the antipsychotic is haloperidol.
- 86. The method of tQ_64. wherein the drug is an anesthetic.
- 87. The method of claim 86 wherein the anesthetic is selected. from the group consisting of lidocaine, tetracaine, dyclonine, dibucaine, cocaine, procaine, mepivacaine, bupivacaine, etidocaine, prilocaine and any one of claims 53 benzocaine.
- 88. The method of claim 37 wherein the anesthetic is lidocaine.
- 89. The method of to 64. wherein the drug is an analgesic.
- 90. The method of claim 89 wherein the analgesic is selected from the group consisting of fentanyl, any one of claims 53 buprenorphine and codeine.
- 91. The method of« to 64, wherein the drug has an action on the central any one of claims 53 nervous system.
- 92. The method of claim 91 wherein the drug is nicotine.
- 93. The method of any one of claims 53 to 64. wherein a nxture of at least two drugs is combined with said blend of polymeric materials.
- 94. The method of claim 93 wherein said mixture of drugs comprises a progestational agent and an estrogen.
- 95. The method of claim 94 wherein said progestational agent is selected from the group consisting of progesterone, 19—norprogesterone, norethindrone, norethindrone acetate, melengestrol, chlormadinone, ethisterone, medroxyprogesterone acetate, hydroxyprogesterone caproate, ethynodiol diacetate, norethynodrel, 17a-hydroxyprogesterone, dydrogesterone, dimethisterone, ethinylestrenol, norgestrel, demegestone, promegestone, and megestrol acetate.
- 96. The method of claim 95 wherein said progestational agent is norethindrone acetate.
- 97. The method of claim 94 wherein said estrogen is selected from the group consisting of conjugated estrogens, esterified estrogens, estropipate, 175- estradiol, equilin, mestranol, estrone, estriol, ethinyl estradiol, and diethylstilbestrol.
- 98. The method of claim 97 wherein said estrogen is 178-estradiol.
- 99. The method of any one of claims 53 to 98. wherein the first and second solubility parameters are different from one another by an increment of at least about 2 (J/cmU‘”.
- 100. The method of claim 99 wherein the first and second solubility parameters are different from one another by an increment of at least about 4 (J/cmfi‘”.
- 101. A method of adjusting the solubility of a drug in a transdermal drug delivery system which comprises the step of blending a plurality of polymers having differing solubility parameters, so as to achieve a predetermined net solubility parameter, wherein at least two of said plurality of polymers have solubility parameters differing by at least about 2 (J/cm’)"’.
- 102. The method of claim 101 wherein the first and second solubility parameters are different from one another by an increment of at least about 4 (J/cmH‘”.
- 103. A method of modulating the delivery rate of a drug from a transdermal drug delivery system of the type having a pressure~sensitive adhesive matrix, which method comprises the steps of: (a) selecting at least two immiscible polymeric materials as components of a multiple polymer adhesive system such that the system has a preselected net solubility parameter which results in a modified solubility of a drug in the system; and (b) combining said at least two polymeric materials with a drug to form a pressure-sensitive adhesive matrix, wherein the matrix achieves a drug delivery rate which is determined by said preselected net solubility parameter and which differs from the delivery rate achieved by a pressure-sensitive adhesive matrix comprising a single one of said at least two polymeric materials as the sole polymeric material.
- 104. The method of claim 103 wherein the drug is intimately mixed with the at least two polymeric materials in the pressure-sensitive adhesive matrix.
- 105. The method of claim 104 wherein said polymeric materials and said drug are combined to form a reservoir device having an adhesive portion comprised of a blend of said polymeric materials.
- 106. The method of any one of claims 1p§_tp 105. wherein said step of selecting comprises the step of measuring the flux rate from various weight ratios of the selected at least two immiscible polymers and choosing the ratio producing a preselected flux rate.
- 107. An improved pressure—sensitive adhesive composition substantially as described herein with reference to the Examples and/or the accompanying drawings.
- 108. A transdermal drug delivery system substantially as described herein with reference to the Examples and/or the accompanying drawings.
- 109. A method of making a transdermal drug delivery system substantially as described herein with reference to the Examples and/or the accompanying drawings.
- 110. A transdermal drug delivery system whenever produced by a method as claimed in any of claims 53 to 100 or 109.
- 111. A method of adjusting the solubility of a drug in a transdermal drug delivery system substantially as described herein with reference to the Examples and/or the accompanying drawings.
- 112. A method of modulating the delivery rate of a drug from a transdermal drug delivery system substantially as described herein with reference to the Examples and/or the accompanying drawings.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IE1992/2897A IE83766B1 (en) | 1992-12-14 | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IE1992/2897A IE83766B1 (en) | 1992-12-14 | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
Publications (3)
Publication Number | Publication Date |
---|---|
IE19922897A1 true IE19922897A1 (en) | 1994-06-14 |
IE922897A1 IE922897A1 (en) | 1994-06-15 |
IE83766B1 IE83766B1 (en) | 2005-01-12 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0591432B1 (en) | Solubility parameter based drug delivery system and method for altering drug saturation concentration | |
US9668981B2 (en) | Device for transdermal administration of drugs including acrylic based polymers | |
CA2331264C (en) | Compositions and methods for drug delivery | |
US8187628B2 (en) | Dermal composition for controlling drug flux comprising two acrylic adhesive polymers having different functionalities and different solubility parameters | |
IE19922897A1 (en) | Solubility parameter based drug delivery system and method for altering drug saturation concentration | |
IE922897A1 (en) | Solubility parameter based drug delivery system and method¹for altering drug saturation concentration | |
IE83766B1 (en) | Solubility parameter based drug delivery system and method for altering drug saturation concentration | |
PT101153B (en) | DRUG ADMINISTRATION SYSTEM BASED ON SOLUBILITY PARAMETERS AND METHOD TO ALTER THE CONCENTRATION OF DRUG SATURATION |